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ABSTRACT 
Introduction:  Head and neck cancers require aggressive multi-modal treatment, 
including a course of radiation therapy.  Mucositis is a common side effect of 
radiation therapy with short- and long-term symptoms and disabilities.  The 
objectives of this body of work were to characterize the myriad of clinical 
manifestations of mucositis and to describe patient-reported scales currently 
available to measure patients’ symptoms (Manuscript #1) and to describe the 
pathological mechanisms that result in these clinical signs and symptoms and 
propose a new treatment based on Ayurvedic medical principles and formulations 
(Manuscript #2). 
 
Methods:  In-depth reviews of articles published in PUBMED were done; articles 
were identified using the following search terms: radiation therapy; head and neck 
cancer; and patient symptoms/reported problems/subjective 
feelings/complications/side-effects. Review of traditional Ayurvedic texts was 
conducted to identify plant compounds effective for general stomatitis and, using a 
bio-prospecting methodology, recent literature was reviewed to ascertain 
mechanisms of action of these compounds.      
 
Results:  Multiple clinician-rated scales use inconsistent terminology and scoring 
rubrics to rate mucositis and often do not correlate with patient-reported 
symptoms.  Only several patient-reported scales currently exist and they measure 
diverse and limited symptoms. However, multiple studies indirectly describe a 
plethora of acute and chronic symptoms resulting in marked disability and 
suffering.  There are multiple metabolic pathways that drive the phases of 
radiation-induced mucositis and current medications are ineffective in controlling 
symptoms and progression.  This results in patient suffering and cancer therapy 
  
protocol interruption.  Using bio-prospecting, seven compounds met the following 
criteria for a novel treatment based on Ayurvedic medicine: can be used internally, 
daily, and as a mouthwash; has anti-bacterial and anti-fungal effects; and enhances 
saliva production, pH balance, and wound healing.   
 
Discussion:  Radiation-induced mucositis is characterized by complex 
pathophysiology and clinical manifestations.   There is a great need to develop 
uniform methods to describe symptoms, which would, in turn, enhance the 
assessment of new interventions to treat mucositis as well as enhance adherence to 
aggressive therapeutic protocols.  Patient-reported scales should be developed and 
should capture the diverse experience of mucositis using patients’ language (see 
poem below).  In addition, clinicians’ measurements should be standardized in 
terminology and content.  A new mouthwash that is based on traditional Ayurvedic 
knowledge, supported by current scientific data, and targets multiple pathways, 
offers a new possibility to treat radiation-induced mucositis.  This proposal is a 
paradigm shift in the drug discovery mechanism in that drug development need not 
always be confined to new molecular entities.  Instead, bio-prospecting of plants 
utilized by ancient knowledge and gained from indigenous medicines may provide 
a new strategy for drug development.   
 
Putting the Patients’ Experience in Their Own Words: Stomatitis 
Anita Hart Balter 
N Engl J Med 1990;322:704 
 
“A fish hook lodges in my throat. 
Spittle, kindergarten paste, thickens everything - even vision. 
Mouth pocked with sores and blisters, swollen ulcerated tongue. 
Topside sandpapered with number 7 coarsest grade. 
Taste buds, saliva glands, seared. 
Cool water, corrosive acid now. 
The tongue rests; teeth become enemies, 
Coiled steel razored wire atop dentate prison walls. 
Only moans escape my lips. I cannot eat or speak. 
Inside, a howl festers. 
Pain lengthens time.  
iii 
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ABSTRACT 
Introduction:  Radiation-induced mucositis is a common and serious complication 
of therapy for head and neck cancer.  There are multiple clinician-rated staging 
systems to describe mucositis but few patient-reported scales to describe the 
impact of mucositis on function and quality of life.   The objectives of this 
literature review were to compile patient-reported symptoms of mucositis in order 
to propose what symptoms and side-effects should be included in future patient-
reported scales.  
 
Methods:  A PUBMED search was conducted to identify patient-reported scales 
that address radiation-induced mucositis using the following search terms: 
radiation therapy; head and neck cancer; and patient symptoms/reported 
problems/subjective feelings/complications/side-effects.   
 
Results:  Multiple clinician-rated scales use inconsistent terminology and scoring 
rubrics to rate mucositis and often do not correlate with patient-reported 
symptoms.  Only several patient-reported scales currently exist and they measure 
diverse and limited symptoms. However, multiple studies indirectly describe a 
plethora of symptoms including pain, xerostomia, dysphagia/odynophagia, altered 
saliva viscosity, gagging/regurgitation, aspiration, lost or altered taste, loss of 
appetite, fatigue, poor nutrition, weight loss, prolonged time to eat, hoarse voice, 
trouble being understood, limited food choices, over sensitivity to hot, cold, spicy, 
sweet and acidic foods, sensation that teeth are loose and cracking/chipping, 
trouble with dentures, over sensitivity when brushing teeth, limitations in jaw and 
shoulder/neck movement, and long-term osteoradionecrosis.    
 
Discussion:  Both patient-reported scales and clinician-measured features should 
be combined to provide a comprehensive assessment of radiation-induced 
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mucositis for head and neck cancer.  Uniformity would enhance the establishment 
of new interventions to treatment the disability and suffering associated with 
mucositis as well as enhance adherence to aggressive therapeutic protocols.  
Patient-reported scales should be developed and rigorously tested for validity, 
reliability and responsiveness and should capture the diverse experience of 
mucositis using patients’ language.  In addition, clinicians’ measurements should 
be standardized in terminology and content.  When paired, such measures will 
capture radiation side effects fully throughout the course of treatment, from acute 
to long-term chronic effects. 
 
INTRODUCTION 
Background   
Despite advances in early detection and effective treatment, cancer remains 
one of the most feared diseases due to its association not only with death but also 
with diminished quality of life.  Although research is producing new insights into 
the causes and cures of cancer, efforts to manage the symptoms of the disease and 
its treatments have not kept pace.1 
Head and neck cancer is the fifth most common neoplasm with at least 
500,000 new cases reported every year.2  Of these, 40% occur in the oral cavity, 
25% in the larynx, 15% in the pharynx, and 7% in the salivary glands.3 The 
treatment protocol involves simultaneous or sequential use of surgery, radiation 
and chemotherapy.  Concurrent chemotherapy and radiation have become the 
current standards of care and are associated with considerable toxicity, particularly 
xerostomia and mucositis.4,5  These side effects not only significantly impair 
quality of life but also result in severe long-term oral disorders among patients who 
have remission from their cancers.4 
Oral mucositis commonly occurs during head and neck cancer treatment 
and is expected to increase in prevalence to 100% as radiation dose intensification 
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becomes part of routine care.6,7,8 Mucositis caused by radiation differs from that 
due to chemotherapy in that radiation damage often is permanent.9  Currently, two 
thirds of patients treated for cancers of the larynx and hypopharynx suffer from 
mucositis.10  The severity of oral mucositis varies from erythema and burning 
mucosal discomfort, to large areas of deep coalescing ulcers that require high doses 
of opioids to manage pain. 11,12 The etiology of mucositis is the unavoidable 
toxicity to normal cells throughout the gastrointestinal track that have a rapid rate 
of turnover, such as the oral mucosa. 13 
Apart from the pain associated with mucositis, additional serious morbidity 
include difficulties in swallowing, chewing, and speaking.  This is particularly 
prevalent when the pharyngeal mucosa is involved.  It is estimated that 93% of 
patients have disturbances in eating.  Chronic pain is also prevalent with an 
estimated 79% of patients having sleep disturbances14,15.  
In summary, oral mucositis is associated with a range of acute and chronic 
symptoms that exert a substantial negative impact on quality of life.  The pain due 
to mucositis can cause functional difficulties in eating, drinking, swallowing, 
speaking, and even sleeping.16,17,18 These effects, in turn, can lead to weight loss, 
anorexia, cachexia, dehydration, and the need for parenteral feeding19,20.  
The control of cancer-related symptoms is a vital aspect of medical care and an 
important clinical goal for patients and health care professionals.21  However, 
measurement of mucositis is not a routine part of medical care.  For example, a 
survey of 46 transplant centers in 16 European countries conducted by the research 
subcommittee of the European Blood and Marrow Transplant Nurses Group found 
that only 59% of centers used standardized assessments for mucositis.  In addition, 
there are no standardized scales or protocols for assessment, and thus no methods 
to gauge success of management.  The first step to address this gap is to understand 
what scales currently exist to measure mucositis and whether they adequately 
address patients’ reports of symptoms and suffering.22 
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Issues Related to Measurement 
Mucositis is a complicated disorder to classify as it involves a complex and 
overlapping cascade of compounds from multiple pathways of injury.  In addition 
to complex interactions in the mechanism of injury there also are feedback loops 
that create new vulnerabilities. Often there also are areas of mucositis at varying 
stages, making the process of measurement more difficult.  Developing a model of 
mucositis is important because it at least gives a framework to measure both 
symptoms and effects of new anti-mucositis agents.  While biological 
measurement is important, it is critical also to keep the patients’ point of view and 
symptoms in focus.  Thus a robust assessment tool needs to address both biological 
and patient-reported perspectives, and ideally would be useful clinically and for 
research.  Such a measurement tool could provide much needed insight into the 
effectiveness of anti-mucositis agents and predict the clinical course and prognosis 
of mucositis. 
In addition to identifying the necessary content of a measurement scale, 
another major hurdle is the lack of a globally accepted validated scoring system. 
The widely used World Health Organization (WHO) and National Cancer Institute 
(NCI) systems were developed to describe toxicities associated with a particular 
chemotherapeutic agent or regimen. These scales combine objective signs of 
mucositis (erythema and ulcer formation) with subjective and functional outcomes 
(pain and inability to eat). Although the developers of these scales intended the 
scorer to consider lesions painful if analgesia masked the pain, in practice many 
scorers ignore this differentiation, most likely resulting in underreporting and 
underscoring of mucositis.  At the other end of the spectrum, there is a scale 
developed by oncology nurses which has a more holistic approach and integrates 
elements such as evaluation of the integrity of the oral mucosa and functional and 
subjective outcomes such as speech quality, avoidance of spicy foods, swallowing, 
lip and mucosal dryness, infection, bleeding, and cleanliness.  Finally, some 
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researchers attempted either to eliminate subjective findings completely or to 
evaluate them independent of objective findings and then integrate them into a 
single comprehensive score. 
 
Objective Scales and Mixed Scales  
There are multiple clinical tools that consider signs, symptoms and 
functional disturbances secondary to mucositis toxicity.  They can be broadly 
divided into scales that focus on patient-reported items (considered ‘subjective’), 
scales that assess observable physician-rated features (considered ‘objective’), and 
mixed scales that have elements of both.   Some scales focus only on one feature, 
such as pain, dysphasia, burning sensation and discomfort.  A comprehensive 
summary of existing physician-rated scales and their scoring rubrics are listed 
below.   
 
-  World Health Organization (WHO) Scale  In 1979 the WHO proposed a 
classification of mucositis according to severity based on 0-4 grades.  Apart from 
objective signs of erythema and ulceration, the subjective symptom of ability to eat 
is also rated.  This is currently the most widely used scale and it addresses three 
components of mucositis: objective signs (such as ulceration), subjective 
symptoms (such as soreness), and functional disturbances (such as inability to eat).  
The WHO scale is widely regarded as the gold standard despite the fact that it has 
not been extensively tested.   The scale is divided into the follow grades: grade 0 - 
absence of mucositis; grade 1 - presence of a painless ulcer, erythema or mild 
sensitivity; grade 2 - presence of painful erythema or ulcers that do not interfere 
with the patient’s ability to take food; grade 3 - confluent ulcerations that interfere 
with the patient’s ability to take solid food; and grade 4 – severe symptoms 
requiring enteral or parenteral support.23 
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-  Radiation Therapy Oncology Group/European Organization Research and 
Treatment of Cancer (RTOG/EORTC) Scale  The RTOG/EORTC Scale is a simple 
scale that considers mucositis based on its absence to the appearance of ulceration 
and/or necrosis.   The RTOG/EORTC is scored similar to the WHO scale in that it 
ranges from a grade of 0 to 4 as follows: grade 0 – no change over baseline; grade 
1 - mild pain but does not require analgesics;  grade 2  - patchy lesions that may 
have serosanguinous discharge, pain requiring analgesics, patches less than 1.5 cm 
and non-contiguous; grade 3 - confluent fibrinous patches, may include severe pain 
requiring narcotics, will be greater than 1.5 cm in size;  grade 4 - necrosis or deep 
ulceration with or without bleeding.24,25 
 
-  National Cancer Institute/Common Toxicity Criteria (NCI/CTC) Scale  The 
NCI/CTC scale was updated in 1998 and classifies mucositis according to the zone 
of appearance.  It similarly is organized into the following grades: grade 0 - no 
pain, ulcers, erythema or soreness; grade 1 - painless ulcers, erythema or mild 
soreness; grade 2 - painful erythema, edema, ulcers, but can eat; grade 3 - painful 
erythema, edema, ulcer, cannot eat; grade 4 - patient requires parenteral or enteral 
support.  The NCI-CTC is used commonly to evaluated mucositis; however, this 
scale is characterized by wide inter-rater variability.26   
 
-  Scale of the Western Consortium Cancer Nursing Research (WCCNR)  The 
Western Consortium Cancer Nursing Research developed a system to evaluate 
mucositis induced by chemotherapy.  This is a 4-point scale with detailed 
descriptions of each stage of mucositis.  This scale is administered by a nurse.  The 
authors consider advantages of this system to be its low complexity (compared 
with scales of multiple variables) and the fact that the description for each stage 
has been selected to describe technical and very intuitive general progression of 
mucositis.27 
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-  Oral Mucositis Scale Rating (ORMS)  The ORMS was designed as an 
instrument to quantify mucosal changes associated with bone marrow transplant.  
The scale delineates specific degrees of mucosal tissue injury and considers the 
visual measurement of erythema and ulceration.28   
 
-  MacDibbs Questionnaire  This is a 15-item questionnaire composed of 9 
subjective questions and 6 objective measurements.  The 9 subjective questions are 
scored on a 5-point rating scale from 0 to 4.  Pain is rated twice - with and without 
swallowing.  The objective items consider number of ulcers in the oral cavity, the 
size of the largest ulcer in millimetres, and the presence of vesicles, reddened 
areas, and white patches.29   
 
-  Vander Schueren Scale  This scale addresses only objective items and is divided 
into the following 5 grades: grade 0 - no erythema; grade 1 - slight erythema; grade 
2 - pronounced erythema; grade 3 - spotted mucositis; and grade 4 - confluent 
mucositis patches which are greater than 0.5 cm in size.30 
 
-  Byfield Scale  This scale considers both patient-reported and clinical features 
according to the following grades:  grade 1 - mucositis with minimal dysphasia, 
thining but no overt break in mucosal integrity; grade 2 - mucositis has significant 
dysphasia, focal mucosal vesicles or denuded patches, symptoms with ingestion of 
only semisolid foods; grade 3 - only fluids are tolerated and there are obvious large 
confluent patches of mucosal denudation; and grade 4 - only parenteral fluids are 
tolerated and there is severe confluent mucosal denudation with bleeding.31 
 
-  Seto Scale  This scale considers both patient-reported and clinical features 
according to the following grades: grade 1 -  localized erythema with no pain; 
grade 2 - generalized erythema without pain or localised erythema or ulcers with 
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mild pain; grade 3 - multiple ulcers or generalized erythema with moderate pain; 
and grade 4 - generalized erythema or ulcers but with moderate to severe pain.32 
 
- Eilers Scale  This scale has 8 objective components in which voice, swallowing, 
lips, capacity to speak, saliva, mucous membranes, gingiva and dentition are 
assessed with a score of 1 (normal) to 3 (definitively compromised).  Mucositis is 
then divided into three grades:  grade 1 - pink and moist mucositis; grade 2 – 
presence of reddened areas or white film without ulcerations; and grade 3 - 
ulceration with or without bleeding.33 
 
- Beck Scale  This scale assesses several objective items, specifically lips, tongue, 
mucosa, gingiva, saliva, dentition, and the capacity to speak, and one subjective 
item, the capacity to swallow.34 
 
- Spikjervet Scale  This scale was developed for bone marrow transplant patients 
and  uses quantitative determinants for some variables and qualitative determinants 
for others variables; these are then summed for a global score.  Features considered 
are atrophy, erythema, pseudomembranous lesions, ulceration, hyperkeratosis, and 
oedema, which are evaluated on a 0-3 scale (0 - normal/no change; 1 - slight; 2 - 
moderate; 3 - severe).  Mucositis is then graded by an observer as follows: grade 0 
- no discoloration or erythema; grade 1 - white discoloration; grade 2 - erythema; 
grade 3 - pseudomembranes; and grade 4 - ulceration.35 
 
- Maceijewski Scale  This scale considers percent of area involved with the 
following grades: grade 0 - normal; grade 1 - mild erythematous area less that 25; 
grade 2 - severe erythematous area 25-50%; grade 3 - area involved greater than 
50%; and grade 4 - confluent mucositis.36 
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- Lindquist/Hickey Scale  This scale includes clinical features and ability to 
eat/drink according to the following grades: grade 0 - normal; grade 1 - presence of 
whitish gingiva with slight burning sensation or discomfort; grade 2 - presence of 
moderate erythema and ulceration or white patches, with pain but patient able to 
eat, drink and swallow; and grade 3 -  presence of severe erythema with ulceration 
or white patches, with severe pain and inability to eat, drink or swallow.37 
 
- Fred Hutchinson Cancer Research Center (FHCRC) Scale  This scale rates 
mucositis in a Likert format: none, mild, moderate, severe, and life threatening.38 
 
- Oral Mucositis Index (OMI)  This scale was developed in 1992 by dental 
professionals to assess  mucositis associated with bone marrow transplantation.  
The OMI is composed of 34 items, including erythema, ulceration, atrophy, and 
oedema and is scored during a dental examination.  A shorter 20-item version of 
the OMI also is available.39 
 
- Walsh Scale  This scale includes more variables for both subjective and 
functional evaluation, such as mucosal integrity, saliva changes, saliva flow, oral 
hygiene, swallowing difficulty, drugs administered, sensation of oral dryness, and 
severity of pain40 
 
- Acute Radiation-Induced Salivary Gland Morbidity Score (ARISGM)  Patients 
receiving cancer therapy often develop transient or permanent xerostomia 
(subjective symptom of dryness) and hyposalivation (objective reduction in 
salivary flow).  Hyposalivation can further aggravate inflamed tissues, increase 
risk for local infection and make mastication difficult.  Many patients complain of 
thickened secretions due a decrease in the serous component of saliva.  The 
ARISGM Score considers side effects related to salivary gland morbidity and 
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xerostomia according to the following grades:  grade 1 - mild dryness, slightly 
thickened saliva, and slightly altered or metallic taste; grade 2 - moderate to 
complete dryness, thick, sticky saliva, and markedly altered taste; grade 3 - not 
defined for acute xerostomia; and grade 4 - acute salivary-gland necrosis.25 
 
- Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 Criteria 
for Xerostomia  This is a grading system for more severe symptoms that includes 
the requirement for total parenteral nutrition (TPN): grade 1 - dry or thick saliva 
without significant dietary alterations, and unstimulated saliva flow rate >0.2 
mL/min; grade 2 -  dry or thick saliva with significant oral intake alterations 
including copious water intake, use of other lubricants, diet limited to purees 
and/or soft moist foods, and unstimulated saliva flow rate 0.1–0.2 mL/min; and 
grade 3 – severe symptoms leading to inability to adequately aliment orally 
requiring intravenous fluids, tube feedings, or TPN, and unstimulated saliva flow 
rate <0.1 mL/min.41 
 
Of all the above scales, the WHO and the NCI scales are most often used 
because they require little time to complete; however, they do require clinical 
experience and expertise in assessing the oral cavity in order to have inter-rater 
reliability. This is particularly true in cases where the mouth is too painful to allow 
complete evaluation and when mucositis extends from one area to another, or when 
there are multiple areas of mucositis.   
The above scales heavily weigh physicians’ perspectives and include only 
some aspects of patient-reported symptoms.  Radiation therapy has both short term 
acute side effects and long-term side effects.  However, patients often are not 
aware of the long-term effects and thus do not attribute these symptoms to 
radiation and do not report them.  As such, physicians may not assess patients for 
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mucositis routinely and instead focus their attention on monitoring for persistent or 
recurrence cancer.  Thus mucositis is often underreported or not reported.      
 
Patient-Reported Scales: the Gap in the Assessment of Mucositis 
A recent cohort study of head and neck cancer patients assessed both 
clinician measurement of oral and pharyngeal mucositis using the National Cancer 
Institute (NCI) and the Oral Mucositis Assessment Scale (OMAS), and then 
compared the findings with patient- reported experiences of oral mucositis as 
measured by the Patient Reported Oral Mucositis Symptom (PROMS) scale.  
There were marked differences in clinician and patient assessments for 2 groups of 
patients: 1) those with high manifestations and minor complaints, called “stoical 
sufferers”, and 2) those with minor manifestation and high complaints called 
“complaining sufferers”.   The authors concluded that clinical observations can 
differ substantially from individual patient’s experiences of mucositis.  42 
There are multiple possible reasons for these discrepancies.  For example, 
variables that are hypothesized to increase mucositis include older age, poor oral 
hygiene, lifestyle, co-morbidities, and smoking history.  It has also been suggested 
that some individuals with genotype variations are susceptible to mucositis. 
Human papilloma virus also can be partially responsible for amplified mucositis 
and associated symptoms.42 
Patient reported outcomes and experiences can augment clinical data and 
may help in assessing the effectiveness of interventions in cancer care.  In clinical 
cancer research, the use of patient reported outcomes has been recommended for 
patients with prostate, ovarian, gynaecologic, oesophageal, and head and neck 
cancer, among other types.  Patients’ reports can be used to monitor symptoms 
such as oral pain, skin changes, dental health, dry mouth, taste, saliva quality and 
quantity, difficulties with swallowing and mouth opening, shoulder disability or 
immobility, vocal problems (including hoarseness), and various social and 
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functional domains of well-being.  In addition to delineating the side effects of 
therapy, patient-reported scales might also be useful to help predict the 
development of mucositis and identify those patients most at risk.  Thus it is of 
paramount importance that patient-reported outcomes be included in interventional 
studies of mucositis, and that they be used to document within-patient progression 
as well as between-patient differences.   
 
What Is Known about Patients’ Symptoms: Objectives of this Review 
Patients with significant mucositis present with a variety of symptoms, 
including pain, dysphagia, odynophagia, excess oropharyngeal mucus, gagging and 
regurgitation, aspiration, difficulties in eating/swallowing, weight loss, and 
respiratory symptoms (a comprehensive summary is provided in Appendix 1). 
To truly understand the symptom burden, scales addressing function and 
quality of life are needed.   This is necessary in the light of studies which have 
demonstrated that patient- reported symptoms tend to be more diverse and severe 
than physician-reported symptoms.43-45 For example, in a recent study to closely 
monitoring the objective and subjective development of mucositis, investigators 
characterized patients’ experiences with terms such as anxiety, distress, pain, 
exhaustion, fatigue and nausea.  They also concluded that there were further 
functional issues related to coping styles, level of distress, personality indices, 
comorbidity, and health related quality of life inventories.  In another study, 
investigators found that 78% of patients with taste disturbances had a positive 
culture for Candida spp. This was 2.58 times more frequent as compared to 
patients without taste disturbances.  In addition, patients with proven Candida spp. 
had a dry mouth in 88% of cases, i.e. 3.11 times more often than patients without 
Candida spp.  Plaques were the most prevalent clinical finding, irrespective of 
other reported symptoms or microbiological results.  These authors concluded that 
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correlating symptoms and findings appears to be helpful as certain symptoms are 
associated with a specifically treatable finding. 46 
Thus incorporating patients’ perspectives is a critical component in the 
comprehensive evaluation of patients undergoing treatment for cancer that results 
in oral mucositis.  The objective of this review, therefore was 1) to assess side 
effects of radiation therapy, particularly with respect to mucositis and its associated 
symptoms and pathways; 2) to review different symptoms reported by patients 
during different stages of radiation therapy; and 3) to review existing patient-
reported scales and consider what symptoms may be missing from these scales.   
 
METHODS 
To determine the spectrum of patient-reported symptoms, a systematic 
literature search was undertaken in PUBMED to find patient-reported scales that 
address radiation-induced mucositis using the following search terms: radiation 
therapy; head and neck cancer; and  patient problems/symptoms/reported 
problems/subjective feelings/complications/side-effects.  Specifically the search 
used the following terms and options:  
("radiation"[MeSH Terms] OR "radiation"[All Fields] OR "electromagnetic 
radiation"[MeSH Terms] OR ("electromagnetic"[All Fields] AND "radiation"[All 
Fields]) OR "electromagnetic radiation"[All Fields]) AND ("Head Neck"[Journal] 
OR ("head"[All Fields] AND "and"[All Fields] AND "neck"[All Fields]) OR "head 
and neck"[All Fields]) AND ("patients"[MeSH Terms] OR "patients"[All Fields] 
OR "patient"[All Fields]) AND ("diagnosis"[Subheading] OR "diagnosis"[All 
Fields] OR "symptoms"[All Fields] OR "diagnosis"[MeSH Terms] OR 
"symptoms"[All Fields]). 
Only scales that were exclusively patient-reported were included.  Few 
studies assessed patient-reported symptoms and none considered long-term 
symptoms.  The Boolean search yielded 6213 studies.  
16 
 
RESULTS 
Etiology of Mucositis and Associated Symptoms  
Radiotherapy is performed in an ionizing fashion - ionic medium is ionized 
making it electrically unstable.  This affects nuclear DNA resulting in loss of 
reproduction and in cell death.  Radiation affects cells in mitotic division and also 
adjacent cells. Tolerance of the adjacent cells is a major dose limiting factor.  Most 
patients are treated with 50-70 Gy of radiation.  This is fractionated by giving 2 Gy 
per day 5 days a week over 5 to 7 weeks.  The radiation is fractionated so as to 
reduce early side effects due to damage to tissues with rapid turnover and to reduce 
late side effect due to damage to tissues with late turnover. 3 
It was traditionally held that mucositis was due to the direct effect of 
chemotherapy or radiation on muscosal tissues.  More recently the following 5-
stage rubric was proposed. 47-54 
1) Initiation of tissue injury due to the direct effect of radiation on the basal 
epithelium begins within hours of therapy.  As a result of radiation, highly reactive 
oxygen species or free radicals are generated as a by-product of oxygen 
metabolism and cause direct cellular damage.  These reactive oxygen species also 
initiate a cascade of injurious molecular events extending to replicating cells and 
causing damage to DNA.  2) Up-regulation of inflammation occurs via generation 
of messenger signals due to free-radical activation of messengers that transmit 
signals from receptors on the cellular surface to the inside of cell. These in turn up-
regulate pro-inflammatory cytokines leading to tissue injury and cell death, as well 
as to damage to epithelium and connective tissues.  These events are associated 
with symptomatic sensations of burning and pain and the start of erythema.  3) 
Signalling and amplification from up-regulation of pro-inflammatory cytokines, 
such as TNF-a and interleukin 6 produced mainly by macrophages, occur and 
cause injury to mucosal cells. Different feedback loops are generated in this phase 
with the same cytokines that target tissues for direct damage also stimulate genes 
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that are responsible for cytokine production.  These feedback loops sustain and 
escalate the severity of mucosal injury even after cytotoxic cancer therapy has been 
discontinued.  4) Ulceration and inflammation occur based in part on metabolic 
by-products of newly colonizing oral microflora.   These organisms replace normal 
colonized micro-organisms which usually help establish and maintain a 
homeostatic environment (i.e. “colonization resistance”) and now are eradicated 
due to radiation.   Production of pro-inflammatory cytokines also is further up-
regulated as a result of this secondary infection.  This is the stage in which there is 
classic expression of mucositis.  Since there is often concurrent neutropenia and 
compromise of oral flora, bacteria colonize and further stimulate macrophage-
directed inflammation.  5) Healing is characterized by epithelial proliferation, as 
well as cellular and tissue differentiation and restoration of the integrity of the 
epithelium. This phase typically starts 2 to 4 weeks after discontinuation of cancer 
treatment.  Healing is governed primarily by regulatory proteins expressed by the 
extracellular matrix.   
  Multiple proteins and extra-cellular species are actively involved 
throughout this process, such as factor Kappa B (stage 1), sphingomyelinases and 
NF-kB transcription factor (stage 2), COX-2 cyclooxygenase, TNF-alpha activated 
NF-kB and C-JUN (stage 3),  
keratinocyte growth factor, matrix metalloproteinases (stage 4), and pro-
angiogenic and epithelial growth factors that may be distinct from normal tissue 
(stage 5).47-53,11 
Although this classification rubric is highly descriptive, it does not 
completely capture the complex mechanism of mucositis which is also 
characterized by overlap and integration of injury.  In particular, the cascade also 
involves multiple pathways, which in turn present great challenges to therapeutic 
management.   Signs and symptoms of mucositis in different phases can be seen in 
the following Figure 1.1. 
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Figure 1.1  Stages of muscositis, associated symptoms and clinical features  54 
 
Other Symptoms Associated with Radiation Therapy Determined from Reported 
Studies 
Currently it is relatively common to administer radiation in an outpatient 
setting.  Unfortunately this leaves the responsibility on the patient to detect, report, 
and manage oral side effects.  However, patients may not attribute all side effects 
to radiation treatment, as was found in one study in which mouth pain and dryness 
were underreported by patients.55  Another study also demonstrated that occurrence 
of mucositis was under documented in medical records compared to interview. 56 
Other symptoms also are seldom reported by patients.  For example, excessive, 
viscous mucus in the mouth and throat is seldom reported but has been shown to 
be one of the most burdensome symptoms57.  Paradoxically, it is not uncommon 
for patients to complain of both dry mouth and excessive throat mucus.58,57 In 
another series of early studies from 1986 and 1989, multiple symptoms were 
19 
 
associated with radiation, including mucositis, accumulation of mucus, candidiasis, 
dysphagia, radiation-induced caries, periodontal deterioration, xerostomia, reduced 
maxillomandibular opening, decrease in resiliency of perioral tissues, and intrinsic 
bone changes. 59,60 
The Care Study Group Systematic Reviews, MASCC/ISOO has 
documented some additional complications due to radiation, including 
biphosphonate osteonecrosis, dysgeusia, oral fungal infection, oral viral infection, 
dental disease, osteoradionecrosis of the mandible and maxilla, and trismus.  In 
addition to xerostomia, salivary gland hypofunction also is associated with lip 
dryness and crusting, fissures of lip commissures, atrophy of dorsal tongue surface, 
atrophic and fragile oral mucosa, difficulties in speaking, chewing and swallowing, 
oral burning sensation, taste disturbances, increased thirst, and sensitivity and pain 
in response to spicy foods and strong flavorings.  Increased salivary viscosity, on 
the other hand, is associated with decreases in flushing and clearance of acid 
production after sugar exposure resulting in demineralization of teeth and 
subsequent dental decay. Compromise of salivary pH leads to increased 
pathogenicity of oral flora and results in dental caries and erosion.61,62 
A review of recent literature shows a preponderance of symptoms such as: pain, 
dysphagia/odynophagia, weight loss, oropharyngeal mucus associated 
gagging/regurgitation, and aspiration11; mouth and throat sores, difficulty 
swallowing, pain, lost or altered taste (ageusia, dysgeusia), excessive secretions 
leading to gagging, nausea, and vomiting; loss of appetite, fatigue, weight loss, and 
aspiration63; xerostomia, ageusia or dysgeusia64; xerostomia and excessive throat 
mucus65; long-term osteoradionecrosis, 66 xerostomia, dysgeusia, dysphagia, 
halitosis, and pain67 ; xerostomia68; increased salivary viscosity, taste changes, 
dysphagia, pain, sore throat, osteoradionecrosis and trismus 60,44; and xerostomia, 
fibrosis, trismus, dermatitis, photosensitivity, radiation caries, soft tissue necrosis, 
and osteoradionecrosis.  69 
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Other studies assessed physiological parameters and found a decrease in pH 
during irradiation, with the lowest value being reached 3 months after the 
beginning of radiation therapy and increasing gradually during subsequent 
months70.  However, salivary pH continued to be slightly acid (pH = 6.87) 12 
months after treatment, and stimulated salivary flow was reduced by 93% 
compared to the beginning of treatment.    
Concurrent with mouth dryness others have demonstrated decreased resting 
and stimulated salivary secretion rates 71,72and increased salivary viscosity due to 
radiation.73  In addition, the NCI has divided complications of head and neck 
cancer into 2 groups based on occurrence – acute (enumerated above) and chronic, 
which includes mucosal fibrosis and atrophy, decreased saliva secretion and 
xerostomia, accelerated dental caries related to compromised saliva secretion, 
infections and soft tissue necrosis and osteonecrosis, taste dysfunction 
(dysgeusia/ageusia), muscular and cutaneous fibrosis, and dysphagia.    
Overall, the most common symptoms reported using our search terms with 
the corresponding number of citations were: mucositis (831); mouth dryness (770); 
xerostomia (762); hyposalivation (774); pain (410); dysphagia (385); weight loss 
(339); caries (193); aspiration (183); taste disturbance (163); trismus (89); fatigue 
(57); sore throat (25); odynophagia (10); sleep disturbance (18); regurgitation (4); 
gagging  (2); and perioral tissue changes, halitosis, and perioral tissue changes (1).  
Thus, this search yielded terms which are generally not considered for mucositis 
such as hyposalivation, caries, trismus, fatigue, regurgitation, gagging, halitosis, 
viscid mucus and perioral tissue changes. 
Patient-Reported Scales 
Because of the diverse array of manifestations characterizing mucostis, 
establishing a comprehensive patient-reported scale to measure symptoms has been 
challenging.   This is compounded by the fact that patient- and clinician-reported 
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measurements may not agree.  Currently the 5 following scales measure only 
patient-reported symptoms.       
 
- M.D. Anderson Symptom Inventory - Head and Neck (MDASI-HN) module  
This 28-item module consists of 3 subscales: 1) 13 core MDASI questions that rate 
the severity of general symptoms associated with cancer; 2) 6 questions assessing 
how severely symptoms interfere with activities of daily life; and 3) 9 questions 
specific to head and neck cancer that address region-specific symptoms, 
specifically mucus in mouth and throat, difficulty swallowing/ chewing, 
choking/coughing, difficulty in speech/voice, skin pain/burning/rash, constipation, 
problems with tasting food, mouth/throat sores, and problems with teeth and 
gums.57 
 
- Functional Assessment of Cancer Therapy-Head and Neck Version 4 (FACT-HN 
module)  This 39-item module consists of 2 subscales: 1) 27 questions assess 
general quality of life issues related to physical, social/family, emotional, and 
functional domains; and 2) 12 items  assess head and neck cancer-specific quality 
of life issues.74 
 
- Oral Mucositis Daily Questionnaire (OMDQ)  This is 10-item questionnaire 
addresses general health (1 question) and the remaining 9 questions focus on head 
and neck cancer. 75 
 
- Oral Mucositis Weekly Questionnaire for Head and Neck Cancer (OMWQ-HN)  
This 12-item questionnaire addresses general health (2 questions) and the 
remaining 10 questions focus on head and neck cancer.76 
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- Patient-Reported Oral Mucositis Symptom (PROMS) Scale  In this 10-item scale 
all questions pertain to head and neck cancer with a visual analogue response 
format.77 
 
The symptoms addressed in each scale and their overlap are summarized in Figure 
1.2.    
 
 
 
 
Figure 1.2  Summary of items addressed in patient-reported scales 
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All 5 scales address issues related to radiation side effects to varying 
degrees.  The MDASI-HN includes the most symptoms, while the other scales 
address different quality of life, social and functional issues.   
Given the broad array of potential symptoms, investigators in one study 
queried patients about the most troublesome and debilitating side effects they 
experienced from radiation therapy.  The most frequently reported side effects 
were lethargy, weakness, dry mouth, mouth sores, pain, and taste changes.  When 
patients were asked to identify the one most debilitating side effect, 20% patients 
stated it was painful sore throat, 18% stated mouth sores and pain, and 14% stated 
dry mouth.  Patients reported these symptoms were accompanied by burning 
causing significant discomfort and inability to eat, drink or swallow.17  In this 
study 90% of  patients also reported taste alteration, including complete loss of 
taste (54%), distorted taste (33%), and reduced taste (13%).  75% reported changes 
in mouth conditions, with most reporting mouth sores, loss of saliva, dry mouth, 
pain, irritation, and sores and blisters on the tongue; 88% also reported changes in 
the throat or oesophagus.   
The overall effect of oropharyngeal mucositis was devastating.  88% of 
patients reported they could not eat or drink due to mucositis or did so with 
extreme difficulty.  83% experienced weight loss from 12 to 79 pounds leading to 
gastric tube placement in 29%.  29% reported speaking difficulties, 38% reported 
depression, 25% reported sleep disturbances, and 13% required hospitalization due 
to mucositis.   
Other investigators reported additional symptoms, some of which are 
seemingly remote from mucositis, such as fatigue, feeling drowsy, feeling 
distressed, lack of appetite,  numbness or tingling, shortness of breath, difficulty 
remembering, nausea, vomiting, choking or coughing, constipation, hair loss, skin 
pain, burning, rash, diarrhea, trismus, hearing loss, distorted smell, and  limited 
range of motion.57  Other reports cite the following additional patient-reported 
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symptoms: poor nutrition, weight loss, difficulty regulating weight, requiring 
liquid supplements, difficulty drinking thin liquids, food getting stuck in the mouth 
and throat, coughing after swallowing, prolonged time to eat, hoarse voice, trouble 
being understood, limited food choices, over-sensitivity to hot, cold, spicy, sweet 
and acidic foods, sensation that teeth are loose and cracking/chipping, trouble with 
dentures, over-sensitivity when brushing teeth, limitations in jaw and 
shoulder/neck movement, and mood changes including anxiety and depression.      
To better understand and predict mucositis it is important to asses and 
grade mucositis with a comprehensive scoring system that considers all patient-
related factors.  Additional factors that should be included are detailed appraisals 
of pain, such as its location, duration, and pattern (i.e. continuous or intermittent).  
Quality of pain also should be recorded according to patients’ qualitative 
experiences and should be recorded with a) descriptors preferably associated with 
nociceptive pain (e.g., sore, dull, hurting, tender, throbbing) and  b) descriptors 
preferably associated with neuropathic pain (e.g., burning, stabbing, tingling, 
shooting, radiating).  Variations in pain, (e.g., due to swallowing, chewing, talking, 
changing body position, and associated with time of day), disturbances in daily 
function due to pain, effects of analgesics, and alternative methods to relieve pain 
(e.g., warmth, cold) also should be included.  Finally, current smoking, abuse of 
alcohol and illegal drugs, and comorbidity and medication use should be included.   
Figure 1.3 incorporates these factors and depicts a plan for comprehensive 
evaluation of patients with mucositis.  
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Figure 1.3  A potential rubric for the assessment of symptoms of mucositis 
that could be part of a comprehensive patient-reported scale  
and a new scoring system 
 
 
In order to advance clinical care and research in this area, more specific 
patient reported quality of life measurements are needed to assess longitudinal 
functional status.  Scales currently used to assess functional status are generic and 
measure global health.   This is particularly important because radiation-induced 
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side effects are both acute and long-term.   Longitudinal functional status measures 
would be better suited to capture chronic side effects of radiation.  Longitudinal 
measures also are useful to cancer researchers and physicians who should 
incorporate baseline and subsequent frequency, severity and distress caused by side 
effects into overall assessments in order to develop effective interventions to 
ameliorate all symptoms.   
Another critical component to consider is the high level of mental distress 
and psychiatric morbidity during treatment and how these impact the interpretation 
of symptoms.  Various mood disturbances undoubtedly contribute to patients’ 
coping strategies and these should be assessed along with other measurements of 
mucositis.  When considered longitudinally, individual change in these 
assessments can help clinicians tailor mental health interventions to each patient’s 
specific needs.    
Mucositis dramatically impacts patients and if not addressed aggressively 
could result in delaying therapy while waiting for symptoms to subside.  This can 
result in compromising the delivery of curative therapy which, in turn, may result 
in significant mortality and morbidity.  Because examining the oral cavity for 
mucositis is complicated and it may be impractical to routinely visualize all 
potentially involved mucosa, the use of patient-reported scales becomes a vital 
component in the decision to proceed with a therapeutic protocol.  
 
DISCUSSION 
Long-Term Use of Scales and How They Should Guide Treatment 
Given the numerous symptoms associated with mucositis it is important to 
assess each symptom to better understand the differential impact of various 
therapies. There is also a need to develop scales that will incorporate uniform 
terminology to better describe outcomes.    
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Despite these needs, mucositis researchers have not reached consensus regarding 
an easy to administer, accurate, and reproducible scoring system designed 
specifically for investigative applications. 
In addition to measuring acute effects, an ideal scale also would address 
long-term side effects of radiation.  Such a scale would provide not only an 
assessment of symptoms, but would also educate patients regarding what to 
monitor for as a radiation side effect.   
Most of the oral symptoms associated with radiation-induced mucositis are 
associated with development and progression of mucositis.  In particular, 
symptoms like hyposalivation, sore mouth and throat, dry mouth, and taste change 
are associated with progression of mucositis.  Some symptoms like having viscid 
mucus, taste changes and hyposalivation can be present throughout the 
development of mucositis and could persist up to one year after radiation.  
Therefore it is important to assess the plethora of symptoms associated with 
mucositis and to adopt therapeutic approaches that prioritize the patients' 
symptoms over diagnostic findings.   
A good scoring system would be one which will consider all patient-related 
factors.  In particular, measurement of symptoms must take into account the 
subjective nature of symptoms and the nuances of language and expressions of 
distress.  Measurement should not be limited to severity or frequency of symptoms 
but also should be linked to functional consequences.  This is supported by the 
well-established clinical observation that although some symptoms may be 
infrequent and appear to be mild in severity, they still can be quite bothersome and 
debilitating to patients.   
A good scoring system also would take into account late side effects.   
These side effects are less often documented for various reasons.  For example, the 
patient does not recognize or attribute these late complications to radiation therapy, 
there are no patient- reported scales to systematically record symptoms, and 
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follow-up visits focus on residual cancer or recurrent disease, thus giving patients 
less time to voice their concerns related to quality of life.  In addition, patients can 
become adjusted to their new situation and learn to cope with many side effects of 
treatment.  This propagates a vicious cycle where lack of pertinent information 
results in lack of awareness on the part of clinicians, which then leads to failure to 
diagnose and manage these side effects.  Patients then do not attribute these 
symptoms to their treatment and thus continue to fail to report these symptoms, 
forming the last part of the vicious loop.   
From the point of view of cancer researchers, inconsistent use of scales and 
inconsistent terminology have hindered progress in understanding mucositis and 
have prevented comparisons across studies or combining data for meta-analysis.  
The true estimate of the impact of mucositis or the assessment of treatment 
effectiveness can only be ascertained if patients' experiences are included in the 
overall assessment based on validated and established scales.  In addition, 
rigorously obtained symptoms can impact clinical care.  For example, one study 
found that control of pain due to mucositis could reduce weight loss; this study 
provides a good example of the potential link between an objective outcome and a 
symptom-control intervention.78 
In summary, both patient-reported scales and clinician-measured features 
should be combined to provide a comprehensive assessment of radiation-induced 
mucositis for head and neck cancer patients.   Patient-reported scales should be 
developed and rigorously tested for validity, reliability and responsiveness and 
should capture the diverse experience of mucositis using patients’ language.  In 
addition, clinician measurements should be standardized in terminology and 
content.  When paired, such measures will capture radiation side effects fully 
throughout the course of treatment, from acute to long-term chronic effects.     
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APPENDIX 1 
Description and Frequency of Symptoms Due to Side Effects of Radiation 
Therapy 
Saliva   Saliva is one of the most versatile fluids of the human body meeting a 
broad spectrum of needs, such as maintaining pH, protecting the oral cavity, 
helping with digestion, and protecting the gastrointestinal epithelium.  The total 
volume of saliva produced varies from 0.5 to 1.5 litre per day and the pH oscillates 
between 6.5 to 7.4. 3 
Additional functions of saliva are cleaning the oral cavity, clearing food 
scraps and bacteria, helping in digestion, aiding the sense of taste, lubricating the 
oral cavity, and promoting chewing, swallowing and speaking.  Salvia also helps to 
protect teeth, aid in the formation of enamel, neutralize acids, act as a first line of 
defence against microorganisms, and provide buffering of gastric reflux. 79,3 
Saliva undergoes qualitative and quantitative changes during radiation 
treatment resulting in reduction of amylase activity, change in pH and buffering 
capacity, and alteration in electrolytes such as calcium, potassium, sodium, and 
phosphate.   
 
Appetite and weight loss  Approximately 38% of patients report weight loss and 
more patients report moderate to severe weight loss in the early recovery stage.57   
In addition, 68% of patients report loss of appetite.  This decreases to 30% by 6 
months post treatment.  Loss of appetite also has been shown to lead to physical 
and psychological symptoms such as anxiety and depression. 80 
 
Swallowing and eating  Approximately 78% of patients report taking longer time 
to eat, with moderate to severe difficulty for 68% of patients.  Effortful swallowing 
was reported in 82% of patients in the early phases of treatment and in 70% of 
patients in later phases. 57 
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Xerostomia  Close to 90% of patients report some degree of xerostomia and 66% 
report moderate to severe symptoms.  Xerostomia related functional deficits are 
reported by many patients, such as chewing/swallowing difficulty (85%) with 59% 
reporting moderate to severe difficulty, and moderate to severe and talking 
difficulty 36%.   
Xerostomia is the most common complication of radiation to the head and 
neck.  The intensity varies but the onset is very pronounced and rapid.  Up to 50% 
of the salivary flow is lost during the first week of radiation and there can be up to 
95% loss of salivary flow during the course of the radiation.   
Xerostomia is both and acute and late side effect of radiation, and is often 
permanent affecting taste, chewing, swallowing, and speech and causing secondary 
infections, change in pH, dental caries, and osteoradionecrosis.  Unfortunately 
these changes can lead to nutritional deficiencies which are difficult to reverse.  
Xerosomia also can be severe enough that it affects sleep58; approximately 28% of 
patients report awaking from sleep because of dry mouth.  Currently-used 
observer-based measurements tend to underestimate the severity of xerostomia and 
under-report xerostomia.   
 
Mucositis  A retrospective study of head and neck cancer reported oral mucositis 
to occur in 83% of patients 82 whereas a prospective study reported mucositis in 
99% for patients with oral cavity, oropharyngeal, laryngeal and hypopharyngeal 
tumours.66 
Mucositis typically occurs within the first hour of radiation and 
progressively worsens during the course of treatment due to the inflammatory 
cascade.  Moderate to severe pain from mouth sores has been reported in 38% and 
moderate to severe dysphagia has been reported in 52% of patients.  Mucositis will 
occur in 100% of patients with increases in radiation dose.  Damage with mucosal 
erythema progresses to pseudomembranous degeneration, frank ulceration, 
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haemorrhage, and secondary infections.57  In one study 100% of patients developed 
some pain during the second week of therapy and severe pain occurred in the fifth 
week of therapy.78 In a retrospective study pain persisted in 52% of patients and 
was reported as severe.82  Although there can be healing, the regenerated mucosa 
does not have the same integrity of normal mucosa.  
 
Excess mucus  According to various studies, thick mucus is reported by 82% of 
patients and results in choking or gagging in 58% of patients, swallowing difficulty 
in 61%,  and difficulty with sleep in 49% of patients.  Patients also report soiling of 
clothes and odour.57 Halitosis was also reported by 33% of patients in one study. 83 
 
Speech and communication  Difficulty speaking, difficulty being understood, and 
hoarseness have been reported in 61%, 59%, and 64% of patients, respectively. 57 
 
Taste alterations  Approximately 83% patients report taste alterations, 52% report 
decreased desire to eat, 65% report alterations in food choices, and 54%  note 
decreased amount of food taken.  Patients also experience persistent taste 
phantoms, such as metallic better, sweet, sour and salty taste. 57 
 
Dental health issues  Approximately 41% of patients report difficulty chewing 
attributed to their teeth or dentures.  50% report their teeth are particularly 
sensitive to hot, cold or sweet foods, 37% report the sensation of loose teeth, 36% 
report cracking or chipping, and 42% report difficulty with dentures. 57 
 
Mucosal sensitivity  Approximately 46% of patients report a burning pain in the 
lining of their throat or mouth and 81% report sensitivity to spicy, hot or acidic 
food.   In 61% of patients mucosal sensitivity affected the types of food they ate.  
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The proposed mechanism is peripheral neuropathy secondary to sensitization of 
nerve endings by inflammation.  57 
 
Range of movement  Limitations in jaw and shoulder/neck movement have been 
reported in 54% of patients.  Trismus (i.e. the uncontrolled inability to open the 
mouth or jaw) and associated fibrosis and dermatitis are late side effect of radiation 
and can be so severe that they impede eating.  Scars of muscle bundles and 
subcutaneous tissues also can result in permanent deformity.   
 
Radiation caries  Radiation caries typically are seen only after one year of 
radiation therapy.  Although they are relatively painless, they are aggressive and 
rapidly compromise teeth.    
 
Soft tissue necrosis  Diminished blood supply from scarring and thickening of 
arteriole walls results in fibrosis and subsequent soft tissue necrosis.  The risk of 
necrosis increases as fibrosis and xerostomia progress. Sharp tooth brushes and 
abrasive brushing techniques can trigger necrosis.  In addition, trauma of any kind, 
including a sunburn to the radiated area, can result in necrosis.   
   
Osteoradionecrosis    Fibrosis affecting arterioles and bone marrow space can 
compromise the production of osteoblasts and osteoclasts, and results in 
osteonecrosis (occurring in 4% to 20% of patients).  The mandible is most prone to 
osteoradionecrosis.   
 
Dysphonia   Approximately 91% of patients report difficulty speaking83.  
Radiation-induced dysphonia is always seen during the treatment of laryngeal 
cancer.  Among non-laryngeal cancer, the prevalence of dysphonia is dose 
dependent and seen when radiation is more than 50 Gy. Patients can present with 
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dysphonia early and this typically worsens within 5 to 15 days.  The onset is 
sudden and can persist for years.  Dysphonia is thought to be due to oxidative 
injury, mucosal oedema, necrosis, epithelial sloughing, and fibrosis.  Objective 
measurements such as grade, roughness, breathiness, asthenia and strain are 
measured.  In addition, patients can have decreased volume, pitch range and 
maximum phonation time associated with increased shimmer, jitter, and subglottic 
air pressure.84  
 
Neuropathic pain and chronic drainage  Neuropathic pain and chronic drainage 
are late adverse effects of radiation85.  In a retrospective study in which the median 
time since radiation was 56 months, investigators found that 12% of patient 
reported symptoms of brachial plexus neuropathy86.  The most common symptoms 
were ipsilateral pain (50%), numbness and tingling (40%), and motor weakness 
with or without muscle wasting (25%).  These investigators also found that 
brachial plexus related neuropathy was under-reported in head and neck cancer 
patients.   
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ABSTRACT 
Introduction:  Radiation-induced muscositis is a common and debilitating side 
effect of treatment for head and neck cancer that often interrupts treatment 
protocols.  There currently are no effective medications to ameliorate the multiple 
manifestations of radiation-induced mucositis.  Ayurvedic medicine has traditional 
formulations (mostly mouthwashes) that are effective to varying degrees in treating 
general stomatitis.  The objectives of this review were: to describe the clinical 
phases, metabolic pathways, and current treatments for mucostis; to conduct 
detailed bio-prospecting from treatments of general stomatitis from Ayurvedic 
traditions based on formulation and bio-activity; and to identify potential plants 
that might be useful in new medications to treat mucositis and to describe their 
traditional uses and contemporarily-ascertained biologic activity.     
 
Methods:  Articles that address current allopathic treatments for mucositis and 
mechanisms of mucosal damage were identified from PUBMED searches.  Eight 
different Ayurvedic texts were consulted to compile information about bio-
prospecting of plants that might be useful to treat radiation-induced mucositis.  A 
rubric of eight key properties potentially critical for the management of mucositis 
was define and seven plants were identified and described regarding their 
effectiveness and known mechanism of action. 
 
Results:  Multiple inflammatory pathways are involved in radiation-induced 
mucositis and contribute to a plethora of symptoms associated with different stages 
of damage and healing.  There currently are no effective medications to arrest 
mucositis.  Novel potential compounds that might have efficacy for radiation-
induced mucusitis were identified by using a bio-prospective method to assess 
mouthwashes used for general stomatitis in Ayurvedic medicine.  First, eight key 
criteria were stipulated: can be used internally, daily, and as a mouthwash; has 
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anti-bacterial and anti-fungal effects; and enhances saliva production, pH balance, 
and wound healing.  Second, compounds had to have strong evidence for at least 
four of these eight properties, some evidence for other properties, be cited in 
Ayurvedic texts, and be described in a mouthwash formulation.  Seven plants met 
all these criteria: Acacia catechu, Azadiracta indica, Glycyhhhiza glabra, Centalla 
asiatica, Emblica officinalis, Terminalica belerica, and Terminalia chebula.  
 
Discussion:  Despite its frequency, symptomatic impact, and health and economic 
costs, there are no effective interventions for radiation-induced mucositis.   In this 
review we propose a mouthwash that is based on traditional Ayurvedic knowledge 
and supported by scientific data that has the potential to ameliorate this adverse 
effect of cancer treatment.   Given there are multiple pathways associated with 
mucositis, therapies that target a single pathway most likely will continue to be 
ineffective.  Our multi-targeted approach offers a plausible alternative.   This study 
supports a paradigm shift in the drug discovery mechanism in that drug 
development need not always be confined to new molecular entities.  Instead, bio-
prospecting of plants utilized by ancient knowledge and gained from indigenous 
medicines may provide a new strategy for drug development.   
 
INTRODUCTION 
Background and Significance 
The incidence of head and neck cancer in India is 30/100,000 in males and 
10/100,000 in females1.  This accounts for 23% of all cancers in males and 6% in 
females in India, while it accounts for only 3% of all tumours in developed 
countries.2  Only the Indian state of Kerala has banned smoking since 1999; 
however, this has resulted in an increase in oral tobacco use.3,4   
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Radiation therapy is the mainstay of treatment for head and neck cancers 
in India.5  The most common side effect of radiation therapy is oral mucositis; two-
thirds of patients starting treatment for larynx and hypopharygeal cancer suffer 
from mucositis shortly after starting therapy.6,7  Symptoms typically begin 1 to 2 
weeks after the initiation of radiation therapy and are characterized to varying 
degrees by erythema, burning mucosal discomfort, and large areas of deep 
coalescing ulcers.  Patients often require high doses of opioids to control pain, 
especially as symptoms worsen with dose escalation.8,9   
Virtually every patient undergoing oral cancer therapy with radiation will 
develop some form of mucositis10; grade 3 mucositis (range 0-4) occurs in about 
60% patients.  Among these, 11% require treatment interruption, which has a 
detrimental effect on cancer control and potential cure.  Mucositis, in turn, often 
triggers a chain of events characterized by difficulty swallowing and chewing, poor 
nutritional and fluid intake, weight loss, sleep disturbances, and psychological 
distress.  In addition, damaged mucosal tissues in the setting of inhibited local host 
responses easily develop lesions caused by microorganisms, including fungi, 
herpes viruses, and a wide variety of bacteria.  This leads to secondary infections 
which further complicate clinical management. 11-13  Additional adverse and costly 
outcomes in severe cases include placement of parenteral feeding tubes, more 
emergency room visits, more unplanned office visits, and longer hospital stays.14    
Maximizing the therapeutic effectiveness of radiation therapy often 
involves increasing total radiation dose and daily fractions and utilizing 
concomitant chemotherapy.  However, chemotherapy also causes erosion of 
mucosal epithelium and thus exacerbates radiation-induced mucositis.  Thus 
mucositis not only is associated with pain and suffering, but also results in reliance 
on parenteral nutrition, administration of narcotics, hospitalization, and sub-
optimal cancer treatment due to interruption in treatment protocols. 15,16 
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The objectives of this review were: to describe the clinical phases, 
metabolic pathways, and current treatments of radiation-induced mucositis; to 
conduct detailed bio-prospecting from treatments of general stomatitis from 
Ayurvedic traditions based formulation and bio-activity; and to identify potential 
plants that might be useful in new medications to treat mucositis and to describe 
their traditional uses and contemporarily-ascertained biologic activity.     
 
METHODS 
Articles that addressed current allopathic treatments for mucositis and 
mechanisms of mucosal damage were identified from PUBMED searches.  Eight 
different Ayurvedic texts were consulted to compile information about bio-
prospecting of plants that might be useful to treat radiation-induced mucositis.  A 
rubric of eight key properties potentially critical for the management of mucositis 
was define and seven plants were identified and described regarding their 
effectiveness and known mechanism of action. 
 
RESULTS 
Mechanism of Mucositis     
A healthy oral mucosa not only serves as a physical barrier to 
microorganisms but also acts as a chemical barrier limiting absorption of many 
compounds into the epithelium.17,18  Oropharyngeal cells undergo rapid renewal 
over a 7-14 day cycle; radiation therapy interferes with mitosis resulting in a 
reduced ability of oral mucosa cells to regenerate.  Although cells that survive have 
an increased turnover rate, they cannot keep pace with cell death and thus patchy 
then confluent denuded areas emerge.  This gradually leads to pseudomembranes 
and ulceration.  Since this process decreases oral intake, poor nutritional status 
further interferes with mucosal regeneration.  The severity of the mucositis 
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depends on the type of ionizing radiation, the volume of irradiated tissue, the daily 
dose, and the cumulative dose.19-25 
Until recently radiation mucositis was thought to result as the direct effect 
of radiation on epithelial tissue.  Only lately clinical studies have revealed that the 
mechanism is more complex and involve trans-tissue toxicity with the submucosa 
playing an important role.  In addition, other co-factors such as oral hygiene, 
genetic predisposition, and an inflammatory cascade can influence this process.26-28 
Five sequential stages in the development of mucositis have been proposed 
- initiation, up-regulation and message generation, amplification and signalling, 
ulceration, and healing (Figure 1).29-30 
 
- During initiation, radiation causes direct injury to basal epithelial cells resulting 
in damage and death of underlying tissues.  This process begins within hours of 
radiation exposure.  Indirect cell damage also occurs which is initiated through a 
non-DNA mechanism mediated by the generation of reactive oxygen species.  
Reactive oxygen species initiate a cascade of several injury-producing pathways 
affecting epithelial cells and fibrobasts.   
 
- In addition to causing direct cell death, free radicals activate messengers that 
transmit signals from receptors on the cellular surface to the inside of cell.  These 
in turn up-regulate pro-inflammatory cytokines and transcription factors such as 
nuclear factor-κB (NF-κB) and NRF-2, which then leads to up-regulation of genes 
that modulate the damage response.  This in turn stimulates macrophages to 
produce pro-inflammatory cytokines such as tumor-necrosis factor-α (TNF-α) and 
interleukin-6 which then lead to further tissue damage.   At this point, the oral 
mucosa becomes symptomatic with sensations of burning and pain, and erythema 
is also seen.  
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- Up-regulation of pro-inflammatory cytokines causes injury to mucosal cells and 
also activates molecular pathways that amplify mucosal injury.  Different feedback 
loops are generated in this phase, the same cytokine that targeted tissues for direct 
damage will also further stimulate genes that are responsible for cytokine 
production.  For example, cytokines such as TNF-alpha can up-regulate and 
amplify the transcription factor NF-kappa B or activate enzymes responsible for 
activating the ceramide pathway that leads to apoptosis.  These feedback loops 
sustain and escalate the severity of mucosal injury even after cytotoxic cancer 
therapy has been discontinued.   
 
- The significant inflammatory infiltrate coupled with colonizing oral microflora 
then leads to ulceration.  Secondary infection in the setting of immunocompromise 
and neutropenia, in turn, up-regulates further inflammation.  Offending organisms 
often are gram positive bacteria, viruses such as herpes simplex, and fungal species 
such as candida.  In addition, the oral mucosa is a habitat for several colonized 
micro-organisms that help to establish and maintain a homeostatic environment 
and prevent colonization of exogenous pathogens. This potent defence mechanism 
called “colonization resistance” is practically destroyed by radiation and thus 
secondary infection is facilitated.     
 
- Epithelial proliferation and cellular and tissue differentiation ultimately occur 
restoring the integrity of the epithelium and thus initiate the process of healing. 
This phase typically starts 2 to 4 weeks after discontinuation of cancer treatment.  
This healing is governed actively by regulatory proteins expressed by the 
extracellular matrix. 26-34 
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Figure 2.1  Proposed phases in the development of mucositis 
 
In addition to these physiological phases, oedema and alterations in 
vasculature occur.  In particular, thickening of the tunica intima and destruction of 
the elastic and muscle fibers of blood vessels result in reduction in lumen size and 
blood flow.  If there is concurrent thrombocytopenia, then oral bleeding can occur 
complicating the clinical scenario.35  
Although this schema is highly regarded, the actual process is more 
complex and multifaceted with considerable overlap and integration of mechanism 
of injury that are currently not known.  Because many pathways are involved, it is 
unlikely that a single drug intervention could fully mitigate the expression of 
clinically significant mucositis.  However, this conceptual model provides a 
preliminary road map for the development of anti-mucositis agents.  This schema 
also has led to closer observation and monitoring of mucositis and to 
improvements in objective and subjective functional assessment tools.   
Multiple symptoms emerge during the different phases of mucositis.  In 
particular, radiation induces transient or permanent xerostomia and hyposalivation, 
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which in turn aggravate inflammation and increase the risk of local infection.  
Patients also report difficulty chewing and thickening of salivary secretions due to 
a decrease in the serous component of saliva.  Different inflammatory markers also 
are associated different phases.  For example, release of CRP, IL-2 and TNF alpha 
occur during the inflammatory phase and secondary infection from bacteria, 
viruses, and fungi occur in the microbial phase.  Figure 2.2 shows various 
symptoms, signs, and pathological features for each phase.     
   
 
 
Figure 2.2  Various symptoms, signs, and pathological features for each phase 
 
There are several patient-related risk factors for mucositis.  These include 
older and younger age, body mass index greater than 25, female gender, and 
African race.  Trauma from ill-fitting dental devices, damaged teeth, poor dental 
hygiene, and oral retainers can increase the risk of mucositis.  Genetic 
polymorphisms also may be associated, such as TT polymorphism in the MTHFR 
gene which metabolizes methotrexate, as well as certain comorbidity, such as 
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Addison’s disease are associated with increased risk.  Interestingly, patients with 
other comorbidity, such as psoriasis, may have a lower risk.36-39 
 
Role of Saliva   
We produce about 600-1000 ml of saliva per day.41  Saliva contains several 
electrolytes (Na+, K+, Cl-, HCO3-,  Ca2+, Mg2+, HPO42-), and over 2000 
different  proteins and peptides, including  amylase, proline-rich proteins, mucins, 
albumin, lipase, alpha-amylase, histatin, cystatin, peroxidase, lysosome, 
lactoferrin, defensins, cathelicidin-LL37, and immunoglobulins (e.g. secretory IgA, 
IgG, IgM).  There are several other small organics such as glucose, urea, uric acid 
and lipids, as well as epidermal growth factor, insulin, cyclic adenosine 
monophosphate-binding proteins and serum albumin.42,43    
Cleaved salivary proteins have multiple different functions which are 
complex and synergistic. Saliva is secreted by major and minor salivary glands and 
content and volume vary for each gland.  In addition, content varies according to 
circadian rhythms, with total protein peaking at the end of afternoon and sodium 
and chloride peaking at the beginning of the morning.  There are also seasonal 
variations with lowest volumes in summer and highest volumes in winter.43-46 
Saliva protein content also varies according to sympathetic/parasympathetic 
stimulation, with sympathetic tone producing low volume high protein content and 
parasympathetic tone producing high volume low protein content.47   Several 
physiological and pathological conditions can modify saliva production 
quantitatively and qualitatively, e.g., smell and taste stimulation, chewing, 
psychological and hormonal status, drugs, age, hereditary factors, oral hygiene and 
physical exercise.48-50  In one study salivary protein concentration, flow rate, 
buffering capacity, and pH were estimated in normal subjects and those with 
gingivitis and periodontitis.  The investigators found a significant rise in total 
protein and albumin concentration in gingivitis and periodontitis subjects.  An 
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overall decrease in salivary flow rate also was observed among the elderly and 
among women.51 
Saliva is the first barrier to infection and the first point where digestion 
takes place.17,18  During radiation there are changes in salivary flow and salivary 
pH.46,47  In one study of children with actue leukemia undergoing bone marrow 
transplant, patients with mucositis had significantly lower levels of salivary 
myeloperoxidase, peroxidase, and immunoglobulin A, and almost double the 
amount of total protein in saliva.   The investigators postulated that although 
ulcerative lesions favour granulocytic infiltration, especially with bacterial 
infection, the lack of granulocytes in peripheral circulation causes a low 
concentration of neutrophils in saliva and subsequently low myeloperoxidase 
levels.52 
Other researchers also noted a decrease of secretory immunoglobulin A that 
persisted up to 5 years after chemotherapy.   In one study, participants who died 
during the study had lower concentrations of serum immunoglobulin compared to 
survivors.53  Albumin abnormalities were found in another study in which higher 
concentrations of albumins in whole saliva were found compared to parotid saliva 
prior to the occurrence of mucositis.54 
 
Pathways of Mucositis   
Radiation damage depends on radiation type, dosage, dose rate, and region 
exposed.  Radiation causes several modes of cell death - necrosis, apoptosis, and 
autophagy, in addition to accelerated normal senescence (during which a cell is 
viable but has altered functions and no longer is capable of proliferation).  
Apoptosis can be divided broadly into intrinsic and extrinsic pathways (the 
extrinsic is triggered by extracellular signals transduced by extracellular death 
receptors and the intrinsic pathway is initiated inside the cell and affects 
55 
 
mitochondrial integrity).  Both pathways converge ultimately at initiation of 
protein lysis and DNA fragmentation. 55 
The pathophysiology of mucositis is complex and involves at least the 
following 14 metabolic pathways: nitrogen metabolism, toll-like receptor 
signalling, NF-kB signalling, B-cell receptor signalling,  P13K/AKT signalling,  
G2/M DNA damage checkpoint receptor,  P38 map signalling, Wnt/B catenin 
signalling,  glutamate receptor signalling, integrin signalling, VEGF signalling, IL-
6 signalling, death receptor signalling, and SAPK/JNK signalling.  These pathways 
overlap, cross over and form feedback loops and thus foster multiple changes in 
epithelia cells, macrophages, cell membranes, connective tissues, mitochondria, the 
nucleus and genes.14,56-60  
 
Treatment of Mucositis 
Different strategies have been attempted to prevent and heal radiation 
induced mucositis.  In a study to identify national treatment practices for 
chemotherapy- and radiotherapy-induced oral mucositis, researchers mailed a 
survey to clinical pharmacists in 200 hospitals throughout the United States.  31% 
were completed and returned from 42 states with most of the respondents from 
university-based medical centers and 45% of hospitals ranged in size from 500-750 
beds.  There was a wide range of agents used for both prophylaxis and treatment; 
69% of respondents reported they had no standard protocols for mucositis and, 
among those that did, 82% of protocols included a single agent or combination of 
ingredients that lack proven efficacy, such as mouthwash mixtures with hydrogen 
peroxide, saline, water, salt, soda, and nystatin. 61 
As part of this review, a literature search was done to characterize current 
treatments for mucositis.  More than 50 randomized trials aimed at prevention, 
palliation, or reduction of radiation-induced mucositis in patients with head and 
neck cancer were identified.  The treatment modalities reported can be broadly 
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divided into locally applied non-pharmacological methods, locally applied 
pharmacotherapies, and systemically applied pharmacotherapies.  The modalities 
used and results from the trials are listed in Table 2.1 and their hypothesized 
locations of action are shown in Figure 2.3.   
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Table 2.1  Treatment modalities for mucositis reported in randomized trials
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Table 2.1 Continued 
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Table 2.1 Continued 
 
 
 
As can be seen from the table, most of these modalities were not effective.   Thus 
despite the frequency, symptomatic impact, and health and economic costs, there 
are no known effective interventions for radiation-induced mucositis.    
 
 
 
 
Figure 2.3  Proposed location of action of various treatment modalities 
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As seen in Figure 2.3, several agents are hypothesized to act during more than one 
stage of mucositis.  This is relevant because different areas of the mouth will have 
mucositis in different stages; thus therapies should have a broad spectrum of action 
and ideally treatment existing mucositis and also prevent emergence of mucositis 
in new locations.  For example, an effective modality would be one that would 
inhibit inflammatory pathways and inhibit feedback loops that prevent healing.  
 
Long-Term Sequelae of Radiation Mucositis 
Chemotherapy-induced and radiation-induced mucositis differ in that 
mucositis induced by radiation often has permanent features.131, 132  For example, 
healed mucosa after radiation may appear pale and be atrophic.  The degree of 
abnormality depends on the extent of injury, extent of mesenchymal cell depletion, 
healing time and recovery rate.  Some ulcers also take a non-healing route and 
progress to soft tissue or bony necrosis.133, 134 
Multiple adverse outcomes result if secondary infection occurs with 
bacteria, viruses or fungi, such as pain hindering adequate nutrition, interruption of 
cancer therapy, decreased quality of life, and systemic infection (Figure 4).  
Potentially fatal bacteraemia in the myelosuppressed state is a possibility in severe 
cases.  The challenge of timely differentiating infected and non-infected mucosisits 
further complicates effective management.135 
There are short- and long-term complications of radiation-induced 
mucositis.  The short term complications start from erythema and can lead to long 
term complications such as malnutrition, fatigue, taste changes, dental caries and 
abdominal disturbances.  
  
62 
 
 
Erythema 
Oedema 
Ulceration 
Pain 
Bleeding 
Partial or absent taste sensations 
Xerostomia 
Local infection 
Systemic Infection 
Malnutrition 
Fatigue 
Dental Caries 
Abdominal Disturbance 
 
 
 
 
Figure 2.4 Short- and long-term adverse sequelae 
of radiation-induced mucositis 
 
 
Moving Forward: A New Paradigm to Treat the Multiple Short- and Long-Term 
Phases of Mucositis Based on Ayurvedic Principles  
It seems unlikely that there will be a single therapeutic agent that will be 
effective in all phases of mucositis, thus a sequenced-therapy approach might be 
more effective.  Such an approach would block or partially block multiple 
pathways at the same time.   
We propose that drug discovery and drug development need not always be 
confined to new molecular entities.  A paradigm shift is proposed that focuses on 
revisiting Ayurvedic medical practices.       
Ayurveda is a legitimate medical system in India for which practitioners 
receive state-licensed, institutionalized medical training.  It utilizes a pharmacopeia 
that has thousands of herbal combinations; often 100 – 200 herbs are combined in 
a single formulation.  The methodology of formulation and preparation is geared to 
enhance bioavailability and synergism.  Currently Ayurveda is used routinely by 
approximately two-thirds of India’s rural population and also is used to some 
Quality 
of life 
Short Term 
Long Term 
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extent in urban populations.  Currently Ayurveda is used in 2458 country hospitals 
with 44,820 beds, in 15,353 dispensaries, and in 495 teaching colleges in India.  In 
addition, there are 7494 drug manufacturing units affiliated with the AYUSH, a 
department of alternative medicine in India with an annual financial growth of 
26.8%.136 
Ayurveda is an ancient tradition based on a holistic approach.  The goals 
are treatment effectiveness through synergetic poly-herbal formulations that are 
safe and devoid of genotoxicity and mutagenic activity.   The emphasis on multiple 
herbal combinations that improve bioavailability offers numerous advantages in 
drug development including reduction of dose and treatment cost.   A reverse 
pharmacology approach inspired by traditional medicine and Ayurveda can offer a 
smart strategy for the identification of new drugs that have multi-site activity 
(Figure 2.5).  137 
 
Figure 2.5 A comparison of allopathic and Ayurvedic approaches  
to pharmacology 
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Allopathic medicine (left side, Figure 5) uses a phase-wise system of drug 
development characterized by first proposing a molecular substance and then 
testing the substance in a sequence of clinical experiments. Ayurveda (right side, 
Figure 5) starts with substances known to be clinically effective in some way, and 
then seeks to identify what elements and in what ways these various components 
are effective; the ultimate goal is then to refine the effective elements.  This latter 
process, termed bio-prospecting, is a cost effective method to identify active 
components as opposed to random screening methods.  However, most 
importantly, this method incorporates the knowledge that isolated compounds from 
plants do not necessarily always exhibit the same properties as the whole plant, as 
the other compounds in the plant may facilitate the absorption, assimilation and 
utilization of the ‘active’ compound.   In addition, when multiple plants are used in 
the same preparation, various compounds in one plant may provide this enabling 
role for the ‘active’ ingredient in another plant.  Furthermore, this process may also 
play a role in the safety of the preparation, such as moderating side effects.     
 
Potential Management of Mucositis with Ayurvedic Medicine 
The Ayurvedic pharmacopeia has mouthwashes derived from herbal 
preparations that are used for oral hygiene and for general stomatitis and 
ulcerations.  Knowledge of these herbal preparations could be utilized in bio-
prospecting of multi-herbal combinations for radiation-induced mucositis.  We 
consulted the following texts for various herbal preparations (details of various 
texts are included in Appendix 2): Charak Samhitha, Sushruta Samhita, Ashtanga 
Hridaya, Sharangdhara Samhita, Chakradattam, Sahasra Yogum, and 
Yogamrutham.   
Mucositis or stomatitis has been studied as a disease in traditional 
Ayurveda.  However, there are no contemporary discussions of radiation-mucositis 
and possible preparations or herbs that might be effective.  Thus, we conducted a 
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comprehensive review of the above Ayurvedic text for herbs that have been 
traditionally used (from time immemorial) for mucositis in general.  A total of 56 
herbs were identified, 47 are listed in Table 2.2.  
 
Table 2.2  Herbs identified from Aruyvedic texts traditionally 
used for general mucositis 
  
 
 
 
(Green represents often, blue moderate, red little, and black none.) Ref 138-269 
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A literature search was then conducted to document how these herbs have 
been used.  Several major properties were hypothesized to be important for 
radiation-induced mucosits: used internally in different formulations; used on a 
daily basis; used as a mouthwash; has potential anti-bacterial and anti-fungal 
effects; stimulates saliva; affects salivary pH; and promotes wound healing.    
Although all 56 herbs were used in internal formulations, 4 were used to a 
lesser extent, 5 herbs had little usage on a daily basis, and 7 herbs had moderate 
usage.  All 56 herbs were used as a mouthwash and only 6 were used moderately.   
Regarding anti-bacterial effects, 33 herbs had evidence for strong anti-
bacterial properties, 19 had moderate anti-bacterial effects, 2 had weak anti-
bacterial properties, and 3 did not have published evidence for anti-bacterial 
properties.  Regarding anti-fungal effects,  
29 herbs had strong anti-fungal properties, 25 had moderate effects, 1 herb did not 
show strong effects, and 1 herb was not assessed for anti-fungal activity.  
Regarding saliva production, only 5 herbs had strong evidence for 
enhancement of saliva production, 24 herbs did not have strong evidence, 12 herbs 
had moderate evidence, and 15 herbs had no evidence of saliva stimulation.   
Regarding pH balancing properties, 33 herbs were found to have only weak 
evidence of pH balance, 18 herbs did not have studies done on pH stimulation, 4 
herbs were found to have moderate evidence, and 1 herb was found to have strong 
evidence of pH balancing property.   
Regarding wound healing, 20 herbs had strong wound healing properties, 
13 herbs had no evidence to support wound healing, 20 herbs had only moderate 
evidence for wound healing, and 3 herbs had no evidence of wound healing.   
In order to hone in on the most promising compounds for future 
investigation, we applied several threshold criteria.  First, we required that there 
should be evidence of both in vitro and in vivo action against mucosits and we 
stipulated that the herb should have strong evidence for at least 4 (50%) of the 8 
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properties; 40 herbs met this criterion.  We then included only those herbs that also 
had any effectiveness for any of the other properties; 19 herbs met this criterion.  
We then considered which of these 19 herbs were discussed in all 7 Ayurvedic 
texts; 13 met this criterion.  Because we propose that a mouthwash formulation 
would be best suited to the management of radiation-induced mucositis, we further 
stipulated the herb had to be described in all texts in 2 or more mouthwash 
formulations; 8 herbs met this criterion.  We eliminated one herb (curcuma longa 
or curcumin) because it has already was tested for mucositis and was not effective.  
Thus, the remaining 7 herbs in combination would address all 8 key properties 
(Table 2.3).  Specifically, the formation could be used internally on a daily basis as 
a mouthwash, and could provide antibacterial and antifungal activity, prevent 
xerostomia, enhance saliva production, promote pH balance, and promote healing.      
 
Table 2.3 Severn herbs meeting all criteria for possible use against 
radiation-induced mucositis 
 
 
 
Acacia catechu, Azadiracta indica, and Glycyrrhiza glabra showed 
excellent activity against gram positive and gram negative bacteria and excellent 
antifungal activity.  While Centella asiatica, Emblica offinalis, and Terminallia 
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chebula exhibited moderate activity against gram positive bacteria, Terminallia 
bellerica showed very weak activity against gram positive bacteria, and all but 
Centella asiatica showed moderate antifungal activity.   
Glycyrrhiza glabra and Embilica officinalis were found to be excellent 
saliva stimulators.  Terminalia chebula showed excellent pH balancing properties 
and the same to a moderate extent was exhibited by Glycyrrhyiza glabra.  
Excellent wound healing activity was found for Azadiracta indica, Glycyrrhiza 
glabra, and Centella asiatica with moderate activity exhibited by Emblica 
officinalis, Terminalia bellerica, and Terminalia chebula . 
Detailed descriptions of these 7 herbs - Acacia catechu, Azadiracta indica, 
Glycyrrhiza glabra, Centella asiatica, Emblica officinalis, Terminalia chebula, and 
Terminalia bellerica, are summarized below.  
 
Acacia catechu  This compound has significant antipyretic, antidiarrheal, 
hypoglycaemic and hepatoprotective effects that were demonstrated in a recent 
study in rats published in 2006.270   Acacia has also shown considerable anti-
microbial activity.  For example, in an in-vitro study, a 50% Acacia catechu 
solution was found to have significant inhibitory activity against gram-positive 
cocci and gram-negative bacilli.  The strains assessed were Straphylococcus aureus 
(112 strains), Staphylococcus epidermidis (112 strains), Enterobacter aerogenes 
(28 strains), Klebsiella pneumoniase (28 strains) and Escherichia coli (28 
strains).271, 272 Other researchers demonstrated that Acacia catechu has activity 
against bacterial (Escherichia coli, Straphylococcus aureus and Salmonella typhi) 
and fungal strains (Candida albicans and Aspergillus niger). 271, 272 - 274 
Acacia catechu also has anti-inflammatory properties in joints, being a dual 
inhibition of cyclooxygenase (COX I and II) and 5-lipoxygenase (5-LOX)275  and 
is a free radical scavenger that might be protective in patients undergoing cancer 
treatment.276     
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Azadirachta indica   This compound has therapeutic potential for controlling 
gastric hypersecretion and gastroesophageal and gastroduodenal ulcers. 277 It was 
also found to have anti-ulcer and ulcer healing properties, including in 
experimental diabetic rats.278, 279 Azadirachta indica has anti-bacterial activity 
against 21 strains of food borne pathogens280, 281  and anti-filarial activity 282 as 
well as anti-viral activity against group B coxsackie viruses.283 
Azadirachta indica has been shown to have anti-proliferative activity 
against several cancer cell lines284 such as prostate cancer cells 285 and decreasing 
CEA levels. 286   Azadirachta indica also attenuated alkylation induced 
carcinogenesis 287 and has chemoprotective effects in murine carcinogenesis model 
systems and in rat mammary and liver carcinogenesis.288  Effects have been shown 
for B 16 melanoma and Ehrlicha carcinoma.289   An Azadirachta indica leave 
preparation was also found to prevents leukocyte apoptosis mediated by cisplatin 
plus 5-fluorouracil treatment in Swiss mice 290 and to restore impaired chemotactic 
activity of peripheral blood mononuclear cells from head and neck squamous cell 
carcinoma 291.  Azadirachta indica also was found to be useful in paracetamol-
induced liver damage. 292 
Regarding anti-microbial effects, Azadirachta indica mouthwash was found 
to inhibit Streptococcus mutans and lactobacilli growth,293 and to have fungicidal 
properties by impeding both fungal growth and aflatoxin production of Aspergillus 
parasiticus. 294 
 
Centella asciatica  This compound has been shown to help cartilage formation, 
collagen synthesis, connective tissue formation, and wound healing. 295, 296, 297 In 
rat studies, Centella asiatica induced proliferation of granulation tissue and 
increased tensile strength in wounds when locally applied and also decreased skin 
necrosis caused by burns. 298  Other studies showed reduced scarring and 
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stimulated skin growth by fostering production of collagen fibers which in turn 
resulted in decreased inflammation and myofibroblast production. 299  
Another study also showed Asiaticoside, a major constituent of the herb, 
promoted wound-healing by reducing lipid peroxide levels in wounds while 
increasing enzymatic (superoxide dismutase, catalase, glutathione peroxidase) and 
non-enzymatic (vitamin E and ascorbic acid) antioxidant levels.300  An animal 
study found that topical application of Asiaticoside used in a 0.2% solution 
improved healing in non-ulcer skin wounds. 301 An overview of three small human 
clinical trials suggests that topical use of an ointment or powder containing an 
extract of Centella asciatica with active triterpene compounds may speed wound 
healing in people with slow-healing skin ulcers. 302 These studies used either a 
topical ointment with a 1% extract concentration or a powder with a 2% extract 
concentration. 
Regarding anti-microbial properties, Centella asciatica has been shown to 
have a broad spectrum of anti-bacterial activities against gram-positive (Bacillus 
subtilis, Staphylococcus aureus) and gram-negative (Escherichia coli, 
Pseudomonas aeruginosa, Shigella sonnei) organisms.  Activity against gram-
positive bacteria is greater than against gram-negatives.  Germacrene compounds 
in the essential oil of Centella asciatica are known to be strong anti-microbial and 
anti-tumour agents .295 
Centella asciatica has been used to treat leprosy, wounds, fever, syphilis, 
acne, allergies, and as a psycho-physical regenerator. 295, 303  Traditionally Centella 
asciatica also has been used as a constituent of a brain tonic for the mentally 
challenged and as an anti-convulsant. 304  
Centella asciatica also has considerable anti-tumour properties and 
showed 100% cytotoxicity to two tumour cell lines (Dalton’s ascites tumour cells 
and Ehrlich ascites tumour cells) after a 3 hour incubation at 37oC. 305 The acetone 
fraction of Centella asciatica extract, a partially purified fraction (3.5 and 8 
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µg/mL), inhibited the proliferation of mouse lung fibroblast cells after exposure for 
6-7 days at 37oC.  The authors suggested it also stimulates the immune system and 
may involve inhibition of DNA synthesis .305 
Regarding the mucosal lining, oral administration of Centella asciatica 
water extract and asiaticoside reduced the size of acetic acid-induced gastric ulcers 
in rats at 3 and 7 days in a dose-dependent manner with concomitant attenuation of 
myeloperoxidase activity in the ulcer tissues. 306  Cell proliferation and 
angiogenesis were promoted in this study.  Centella asciatica also protected the 
gastric mucosa by improving the integrity of the mucosal lining.  This may be due 
to a reduction of myeloperoxidase, a decrease in the recruitment of neutrophils, or 
to its free radical scavenging activity. 307  
 
Glycyrrhiza glabra  This compound is probably the most outstanding herbal 
remedy for mouth sores.  Glycyrrhiza glabra  is licorice root and it is a potent anti-
inflammatory agent and tissue healer.  In one pharmacological study, the anti-
inflammatory effects of Glycyrrhiza glabra exceeded hydrocortisone and 
amidopyrine.   
Regarding the mucosa, a biochemical and histochemical study done on rats 
with Glycyrrhiza glabra and Terminalia chebula showed improved secretory 
effects on Brunner’s gland and subsequent excellent protection against duodenal 
ulcer. 308 Flavanoids of Glycyrrhiza glabra showed anti-H Pylori effects and may 
be useful as a chemo-protective agent for peptic ulcer and gastric ulcer. 309  
Glycyrrhiza glabra also has a wide range of anti-viral effects with in-vitro 
studies showing anti-viral activity against HIV-1, SARS related coronavirus, 
respiratory syncytial virus, arboviruses, vaccinia virus, and vesicular stomatitis 
virus.  Glycyrrhiza glabra also reduced hepatocellular damage in chronic Hepatitis 
B and C and reduced the risk of hepatocellular carcinoma in hepatitis C induced 
cirrhosis.  Reduction in mortality from herpes simplex virus encephalitis and 
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influenza A virus pneumonia 310  and potent anti-viral activity against Japanese 
encephalitis virus 311 also have been shown. 
Glycyrrhiza glabra has known activity against both gram-positive and 
gram-negative bacteria. 312  Glabridin, an active constituent of Glycyrrhiza glabra 
root, was found to be active against both yeast and filamentous fungi. 313, 314, 315  It 
may also have effective anti-microbial activity against MRSA. 316   
In-vitro studies also showed Glycyrrhiza glabra to be protective against 
gamma radiation 317 and to protect mitochondrial function against oxidative 
stresses. 318 It also had anti-oxidant activity with free radicals scavenging effects in 
another study showing higher anti-oxidant activity compared to commercial anti-
oxidants. 319, 320 Glycyrrhiza glabra also exhibited free radical scavenging activity, 
metal chelation and antioxidant power in another study.321  Glycyrrhiza glabra also 
potentiated anti-tumour and anti-metastatic effects of cisplatin. 306  
 
Emblica officinalis, Terminalia bellerica, and Terminalia chebula  These three 
berries  have been used in Ayurveda as an anti-oxidant trio for many diseases.   
 
Emblica officinalis has been shown to have a major role in mucin protection and 
regeneration through its effects in healing stomach ulcers due to nonsteroidal anti-
inflammatory drugs.322 In a series of studies, acute gastric ulcer models induced in 
rats by aspirin, ethanol, cold restraint stress, pyloric ligation, and acetic acid in rats, 
showed that Emblica officinalis had significant ulcer protective and healing effects.  
Effectiveness was attributed to enhancing both offensive and defensive mucosal 
factors.323     
In another study, oral administration of Emblica officinalis at doses 250 
mg/kg and 500 mg/kg significantly inhibited the development of gastric lesions, 
decreased pyloric-ligation induced basal gastric secretion, and titratable acidity and 
gastric mucosal injury.  It also was protective against ethanol-induced depletion of 
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stomach wall mucus and reduction in non-protein sulfhydryl concentration.  
Histopathological analyses have concurred with pharmacological and biochemical 
findings.  324 
Two independent studies showed Emblica officinalis also exhibited anti-
oxidant hepatoprotective properties and also offered protection against chemical 
carcinogenesis. 325,326  In addition, Emblica officinalis also showed considerable 
anti-proliferative activities for in-vitro tumour cell line growth and protection 
against cytotoxic effects of arsenic.327, 328 It also demonstrated free-radical 
scavenging activity.  329,330  Emblica officinalis also has some reported 
antimicrobial activity.    
 
Terminalia chebula  This compound has multiple effects.  In the GI tract this 
compound has been shown to improve gastrointestinal motility 331, to have short- 
and long-term anti-diabetic activity in rats, 332 and to have activity against 
helicobacter pylori. 333 
Terminalia belerica also has anti-cholinergic effects which supports its use 
in hyperactive gastrointestinal disorders in folklore medicine.334 
Terminalia chebula has been shown to be effective against cancer cells 335 
and to be protection against Fe-NTA-induced renal carcinogenesis and oxidative 
damage. 336   Terminalia belerica was also found to have anti-oxidant properties337.  
One recent study provided preliminary data that Terminalia belerica may be 
synergistic with doxoruicine and cisplantin as a growth inhibitory agent. 338   There 
may also be a role for  Terminalia belerica in dermal wound healing. 339 In high 
concentrations Terminalia belerica inhibited salmonella activity. 340   
 
Triphala  Is an Ayurvedic formulation composed of Terminalia chebula, 
Terminalia belerica and Emblica officinalis.  Its enteroprotective effects in equal 
formulation (1:1:1) and unequal formulation (1:2:4) were studied and the results 
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suggested that the unequal formulation provided significantly more protection than 
the equal formulation against methotrexate-induced damage in rat intestine. 341 As 
a group, all three herbs have been reported to have antioxidant and free radical 
scavenging activities 342,343,344 and to have considerable protective effectives 
against indomethacin-induced stomach ulceration when compared with 
misoprostol.   
 
Other formulations with multiple compounds also have demonstrated 
effectiveness.  For example, Acacia catechu, Glycyrrhiza glabra, and Terminalia 
Chebula showed high anti-oxidant activity in one study 345 and Azadirachta indica, 
Terminalia chebula, and Terminalia bellerica showed some cancer curative 
properties.346  Major effects for each compound are summarized in Table 2.4. 
 
Table 2.4  Summary of active effects of seven identified compounds 
 
Acacia catechu   Gram positive cocci, gram negative bacilli; 112 strains 
staphylococcus aureus, 112 strains Staphylococcus 
epidermidis, 28 strains Enterobacter aerogenes, Klebsiella 
pneumoniae, Escherichia coli, Salmonella, Candidata, 
Aspergillus niger, antifungal, dual inhibition COX 1 and 
COX 2 
Azadirachta indica    Anti-ulcer, ulcer healing, anti-bacterial, 21 strains food-
borne pathogens, fungicidal, chemoprotective effects, 
prevents leukocyte apoptosis, streptococcus mutans 
Centella asciatica   Proliferation of granulation tissue, non-ulcer skin wounds, 
necrosis, collagen formation, leprosy, anti-tumour, acetic-
acid induced gastric lesion 
Glycyrrhiza glabra   Chemoprotective agent for peptic and gastric ulcer, anti-
viral vesicular stomatitis virus, yeast, filamentous fungi, 
gram positive and negative in vitro protection of gamma 
radiation, mitochondrial protection against gastric lesions 
Emblica officinalis Ulcer protection and healing, defensive mucosal factor, 
mucin protection, healing of NSAID stomach ulcers, 
radical scavenging activity 
Terminalia bellerica Anti-salmonella, hyperactive gastrointestinal disorders, 
enteroprotective 
Terminalia chebula Dermal wound healing, improved gastrointestinal motility, 
anti-caries, increase pH and buffering 
 
75 
 
The potential therapeutic role for mucositis for each of these herbs was 
ascertained from the literature and the possible location of action(s) along the 
complex biological cascade of mucositis was considered.  The herbs were found to 
act on multiple targets and have multiple anti-inflammatory properties; such as 
inhibiting pro-inflammatory cytokines such as interleukin 2, COX 1 and 2, 
interleukin-1 beta, interleukin 6, tumor necrosis factor, interleukin 1, and nuclear 
factor kappa-B.  In addition, some herbs also potentiated keratinocyte growth 
factor and were excellent anti-oxidants.  The Ayurvedic knowledge and literature 
review suggest that these herbs would have action against radiation-induced 
mucositis at multiple targets and would be capable of inhibiting multiple pathways.  
These are summarized in Table 2.5. 
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Table 2.5 Array of anti-inflammatory effects  
of the seven identified compounds 
 
 
 
Location of Action of the Seven Identified Compounds    
These seven compounds potentially have multiple sites of action along the 
inflammatory pathways associated with mucositis.     
 
Acacia catechu  This compound was found to have dual inhibitory activity of 
COX-2 and 5-LOX (5-lipoxygenase). 347  A study that assessed flavacoxid from 
Acacia catechu found that this substance affected COX-2, 5-LOX, tumour necrosis 
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factor-α (TNF-α), interleukin (IL)-6, IL-10, extracellular-regulated-kinase 1/2 
(ERK), JunN-terminal kinase (JNK), NF-κB, and β-arrestin 2 protein expression in 
mice in a positive way.  Flavacoxid also inhibited the mitogen-activated protein 
kinases (MAPKs) pathway, preserved β-arrestin 2 expression, reduced blood 
LTB4, PGE2, TNF-α and IL-6, and increased IL-10 and lipoxin A4 serum levels.   
Treatment with flavocoxid also was found to be protective against the histologic 
damage induced by CLP, and to reduce the myeloperoxidase (MPO) activity in the 
lung and liver. 348 
 
Azadiracta indica  This compound was found to have effects on IL-12 production 
by  mediating activation of the P38/MAPK pathway and the ERK1/2 signalling 
pathway  which influences interferon gamma and tumour necrosis factor alpha. In 
addition this compound has effects on natural killer cell-mediated cytotoxicity of 
tumour cells associated with CD40–CD40L-mediated endogenous production of 
interleukin-12.349  Azadiracta indica also down regulates interferon-gamma (IFN-
γ) and tumour necrosis factor-alpha (TNF-α).  Nimbolide present in Azadiracta 
indica down regulates IGF-1 (insulin like growth factor 1), proliferating cell 
nuclear antigen, phosphoinositide 3-kinase, nuclear factor kappa B, extracellular-
signal-regulated kinase, Ras, Raf-1, IkB kinase, IKK epidermal growth factor 
receptor, and matrix metalloproteinases.350-352 
 
Glyccyrrhiza glabra  This compound inhibits TNF-alpha activated JNK/c-Jun 
and  IκB/NF-κB signaling pathways without affecting extracellular signal-
regulated kinase 1/2 and p38.  Glyccyrrhiza glabra blocks ERK1/2 activation and 
inhibits expression and activation of matrix metalloproteinases and the 
phosphorylation of ERK1/2 and JNK1/2.  These inhibitory effects are associated 
with an up regulation of tissue inhibitor of metalloproteinase-1 and a down 
regulation of the transcription factors NF-κB and activator protein 1 signalling 
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pathways.  Glyccyrrhiza glabra also inhibit migration and invasion of cancer cells 
by reducing the expression of the P13K/AKT signalling pathway.353-355 
 
Centella asiatica   Substances in this compound, such as madecassoside attenuate 
phosphorylation and inhibit p38 MAPK and phosphatidylinositol-3-kinase 
(PI3K)/AKT signalling.  Centella asiatica prevents lipopolysaccharide induced 
nuclear factor-kappa B (NF-kappaB) translocation from the cytoplasm into the 
nucleus, and also inhibits phosphorylation of extracellular signal-regulated kinase 
1/2 (ERK1/2) and p38.   Other Centella asiatica substances, such as asiatic acid 
and asiaticocide, also inhibit lipopolysaccharide induced nitric oxide and 
prostaglandin E2, as well as inhibit inducible nitric oxide synthase and 
cyclooxygenase-2.   There is a dose-dependent response for asiatic acid and 
reduction of interleukin-6, IL-1β, interleukin-1β, and TNF-α.   356-357 
 
Emblica officinalis  This compound effectively inhibits UVB-induced photo-aging 
in human skin fibroblast via its strong ROS scavenging ability.358  Emblica 
officinalis extracts or purified components also inhibit NF-kappa B.   One 
substance, Quercetin, has been found to prevent epidermal growth factor receptor-
induced EMT via the EGFR/PI3k/Akt/ERK1/2 pathway and by suppressing 
transcriptional repressors.359-361  Smad 3 inhibition also is exhibited. 362 
 
Terminalia bellerica  This compound shows VGEF reduction which helps in 
tumour growth inhibition.   T bellerica was found to down regulate the p13/Akt 
signalling pathway.  Terminalia bellerica effectively inhibits NF-kB/DNA 
interactions and reduces TNF-alpha and pro-inflammatory IL-8 expression.363,364 
 
Terminalia chebula  This compound  suppresses migration, proliferation and 
inflammatory mediator production in macrophages.  It also reduces nitric oxide 
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production, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-
2) expression.  Terminalia chebula has inhibitory effects on metalloproteinase-9 
(MMP-9) expression and down regulation of mitogen activated protein kinases 
(MAPKs) signalling molecules.  Smad 3 inhibition also is exhibited.365  Terminalia 
chebula has also been shown to inhibit NFkB, COX-1, COX-2, 5-LOX,  and TNF-
alpha.   Leutolin found in chebula inhibits Iκ-B-α degradation and subsequently 
inhibits nuclear factor-κB p65 translocation to the nucleus.  In addition, luteolin 
blocks the phosphorylation of ERK1/2, c-Jun N-terminal kinases, and p38 
mitogen-activated protein kinases (MAPKs).366-368 
 
Emblica officinalis, Terminalia chebula, and Terminalia bellerica in combination 
prevent production of free radicles and decrease lipid peroxidation.  These three 
berries in combination also inhibit pro-inflammatory markers IL-1b, IL-6, TNF-a, 
VGEF, prostaglandin E2, and COX-2 by blocking the NF-kB mediated 
inflammatory pathway.  365 
 
Toxicity  
With respect to toxicity, none of these 7 compounds has reported toxicity.  With 
respect to adverse effects, only 3 studies have been reported so far: Centella 
asiatica – no side effects 369 and sedation with chronic administration at high doses 
370; and Azadiracta indica - infertility at high doses 371 
 
DISCUSSION 
Mucositis occurs as a result of a complex cascade of biological events with 
multiple signalling pathways involving multiple molecules and cytokines.  The 
understanding of these mechanisms is in the early phases; however, research to 
date has already elucidated complex biological pathways and identified numerous 
potential therapeutic targets.   Overall, it is now known that mucositis develops as 
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a consequence of related and interacting biologic events, culminating in injury and 
apoptosis of basal epithelial cells and resulting in the loss of epithelial renewal and 
in the subsequent development of ulcerations and atrophy.  It is also known that 
patient factors, such as age, nutritional status, and genetic predisposition play 
important roles in the development of mucositis. 
  It also seems apparent that while it is promising that multiple pathways 
and potential therapeutic targets have been identified, blocking all these pathways 
might be required to inhibit mucositis.   In particular, therapeutic agents should 
have the following properties: have direct and indirect cytoprotective activity; have 
anti-bacterial and anti-fungal activity; prevent xerostomia; and foster saliva 
production and pH balance.   
In this review bio-prospecting was done using traditional Ayurvedic knowledge 
and practices as the discovery engine because this is cost effective and potentially 
more effective compared to random screening methods.   Seven potentially useful 
plants were identified with scientific evidence collated from the literature and 
supported by Ayurvedic texts that cite their use in mouthwashes.  Our review 
showed a combination of Acacia catechu, Azadiracta indica, Glycyrrhiza glabra, 
Centella asiatica, Emblica officinalis, Terminalia bellerica, and Terminalia 
chebula might be useful to inhibit and moderate radiation-induced mucositis.  The 
Ayurvedic pharmacopeia also is a resource for formulation and preparation of 
mouthwashes.  In the traditional method, herbs undergo decoction, a method of 
mashing then boiling to retrieve dissolved chemicals from herbal or plant material.  
The products are then standardised by weight and volume and added to oil and 
ground herbal paste to formulate a mouthwash.  The method permits extraction of 
water soluble and fat soluble particles and combining them in the same 
preparation.   
A particular advantage of this method is that multiple compounds are 
included in a formulation.  Isolated compounds from plants do not necessarily 
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exhibit the same properties or activity as unrefined extracts at comparable 
concentrations of the active component.  In addition, other compounds in plants 
play an important role in facilitation, absorption, assimilation and utilization of the 
active ingredient.  Other compounds also play a major role in providing synergetic 
action, especially when multiple plants are used in the same preparation.  
Additional benefits include potential inhibition of multi-drug resistance and 
decreased cost, as isolates are often expensive and unavailable in bulk quantities 
compared to whole plant extracts which can be produced locally.   
Ayurvedic preparations also are not typically associated with side effects, 
as they have been used widely and daily for centuries.  For example, traditional 
people from Kerala, a southern state of India, drink water boiled with Acacia 
catechu daily; Azadiracta indica is used internally and externally as an antibiotic 
and antifungal agent; Glycyrrhiza glabra is chewed as an adjuvant therapy in 
diabetes and is given to infants as a fungicide; Centalla asiatica is used as a nerve 
tonic in children and the elderly; Emblica officinalis is used in cooking and as a 
berry; and Terminalica belerica and Terminalia chebula are used daily to aid 
digestion.  All seven herbs are also used as adjuvants to synthetic ingredients in 
different mouthwashes currently commercially available on the market.  
Specifically, the following parts of the plant are used: the dry stems of Acacia 
catechu and Azadiracta indica; the dry root of Glycyrrhiza glabra; the wet whole 
plant of Centella asiatica; and the dry fruit without the seed of Emblica officinalis, 
Terminalia belerica, and Terminalia chebula.    
In summary, the consequences of mucositis in the treatment for head and 
neck cancers are broad and include radiation dose reduction, temporal interruption 
in radiation protocols, reliance in parenteral nutrition, administration of narcotics, 
hospitalization and morbidity.  Despite its frequency, symptomatic impact, and 
health and economic costs, there are no effective interventions for radiation-
induced mucositis.  In this review we propose a mouthwash that is based on 
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traditional Ayurvedic knowledge and supported by scientific data that has the 
potential to ameliorate this adverse effect of cancer treatment.  Given that the 
pathobiology of mucositis is not completely understood and that therapies targeted 
at a single site most likely will continue to be ineffective, our multi-targeted 
approach offers a plausible alternative.   The study also supports a paradigm shift 
in the drug discovery mechanism in that drug development need not always be 
confined to new molecular entities.  Instead, bio-prospecting of plants utilized by 
ancient knowledge and gained from indigenous medicines may provide a new 
strategy for drug development.   
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APPENDIX 2 
 
Text of Ayurvedic Medicine 
Charak Samhitha 
This is one of the oldest classic text of Ayurveda.  The compendium by Charak is 
believed to have been written around 400-600 BC; there are some claims it dates to 
much earlier (5000 years old).  It has 120 chapters with 8 sections:   
Sūtra (general principles) - 30 chapters deal with healthy living, collections of 
drugs and their uses, remedies, diet and duties of a physician. 
Nidāna (pathology) - 8 chapters discuss the pathology of eight chief diseases. 
Vimāna (specific determination) - 8 chapters address pathology, various diagnostic 
tools, medical studies and conduct. 
Śārīra (anatomy) - 8 chapters describe embryology and anatomy of the human 
body. 
Indriya (sensorial prognosis) - 12 chapters elaborate on diagnosis and prognosis of 
diseases of the basic senses. 
Cikitsā (therapeutics) - 30 chapters deal with special therapy. 
Kalpa (pharmaceutics and toxicology) - 12 chapters describe usage and preparation 
of medicine. 
Siddhi (success in treatment) - 12 chapters describe general principles of 
'Panchkarma' (detoxification). 
A rational approach to causation and cure of disease and introduction to objective 
methods of clinical examination are unique scientific contributions made by the 
author.  
 
Sushruta Samhita   
This text was written during the 3rd or 4th century BC.  It is composed of 184 
chapters describing 1,120 illnesses, 700 medicinal plants, and 64 preparations 
based on mineral sources and 57 preparations based on animal sources.  The text 
also discusses in detail surgical techniques including incision, probing, extraction 
of foreign bodies, hernia repair, alkali and thermal cautery, tooth extraction, 
caesarean section, haemorrhoid and fistula management, laparotomy, management 
of perforated intestine, fracture types and management, traction, manipulation, 
apposition, stabilization and fitting of prosthesis, and cataract surgery. 
  
Ashtanga Samgraha 
This text is an encyclopedic compendium of all the eight specialized branches of 
Ayurveda. Vegbhata, who flourished in the 7th century AD, is credited as having 
composed this text.   It is written in prose and has details of the 8 sections of 
Ayurveda: internal medicine, surgery, gynaecology and paediatrics, rejuvenation 
therapy, aphrodisiac therapy, toxicology, psychiatry or spiritual healing, and ENT 
(ear, nose and throat). There are subsections on longevity, personal hygiene, causes 
of illness, influences of season and time on the human organism, types and 
classifications of medicine, the significance of the sense of taste, pregnancy and 
possible complications during birth, individual constitutions, and various aids for 
establishing a prognosis. There is also detailed information on five action-therapies 
(pañcakarma) including therapeutically induced vomiting, use of laxatives, 
enemas, and complications that might occur during such therapies and necessary 
medications.  
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Ashtanga Hridaya  
This text was written in the 7th century AD and the translation of its name is Heart 
of Medicine.  The text is written in a poetic manner and contains approximately 
7120 poetic verses focusing on the 8 sections of Ayurveda and surgery.  Social and 
preventive medicine also are included.  
 
Sharangdhara Samhita 
This text has 32 chapters and 2600 verses and can be broadly divided into the 
following 3 sections: 1) weights, measurement and time and place to collect herbs, 
and anatomy, physiology and diagnostics;  2) different herbal preparations, 
methods of preparation, precautions and purification of herbs and minerals; and 3) 
cleansing techniques, detoxification and treatment methods. 
 
Chakradattam 
This text was written in 1060 AD and contains extensive Ayurvedic formulations 
and is a comprehensive text on pharmacology.  The purification of many minerals 
is described.  In addition, cost effectiveness and simple single drug remedies are 
addressed.    
 
Sahasra Yogum  
This text is considered to be the ‘practical prescriber’ with more than 1000 
Ayurvedic poly- herbal formulations and home remedies described.   
 
Yogamrutham 
This text provides information about different herbal and mineral formulations and 
their uses.   
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